<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">100%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content"> To optimize your RAG system, focus on improving the performance on complex questions as they currently have no score (evaluated component: Generator). This will enhance the RAG&#39;s ability to handle more intricate queries effectively. Additionally, ensure that the knowledge base covers a diverse range of information within the Antiretroviral Therapy topic to maintain equal performance across all topics.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"0ea11bdf-f556-4c82-b260-f6eef07c2e40":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p1431","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p1433","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p1440","attributes":{"factors":["Antiretroviral Therapy"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p1441"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p1442"},"title":{"type":"object","name":"Title","id":"p1438","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1460","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1428","attributes":{"selected":{"type":"object","name":"Selection","id":"p1429","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1430"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"AAAAAAAAWUA="},"shape":[1],"dtype":"float64","order":"little"}],["metadata_values",["Antiretroviral Therapy"]],["colors",["#a50026"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1461","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1462"}}},"glyph":{"type":"object","name":"HBar","id":"p1457","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1458","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1459","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1469","attributes":{"data_source":{"id":"p1428"},"view":{"type":"object","name":"CDSView","id":"p1470","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1471"}}},"glyph":{"type":"object","name":"HBar","id":"p1466","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1467","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1468","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1479","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p1473","attributes":{"selected":{"type":"object","name":"Selection","id":"p1474","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1475"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p1480","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1481"}}},"glyph":{"type":"object","name":"Line","id":"p1476","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p1477","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p1478","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1439","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p1453","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p1448","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p1449"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p1450"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1451"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1443","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1444","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1445"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1446"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1447","attributes":{"axis":{"id":"p1443"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1452","attributes":{"dimension":1,"axis":{"id":"p1448"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p1472","attributes":{"location":100.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p1482","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1483","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p1479"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"0ea11bdf-f556-4c82-b260-f6eef07c2e40","roots":{"p1431":"af4aa43f-ffe4-4001-9046-255a945e8d2e"},"root_ids":["p1431"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="af4aa43f-ffe4-4001-9046-255a945e8d2e" data-root-id="p1431" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"f17ed850-2d57-4486-b267-b862bfc98f2d":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p1362","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p1293","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p1246","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1255","attributes":{"start":-0.9166807293891908,"end":8.752451610565185}},"y_range":{"type":"object","name":"Range1d","id":"p1256","attributes":{"start":-2.575758934020996,"end":7.232198476791382}},"x_scale":{"type":"object","name":"LinearScale","id":"p1257"},"y_scale":{"type":"object","name":"LinearScale","id":"p1258"},"title":{"type":"object","name":"Title","id":"p1253","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1286","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1243","attributes":{"selected":{"type":"object","name":"Selection","id":"p1244","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1245"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"XV2QQPw6eEBUHkhAippuQPR/fEAQUm1AnHwVQOAm3D9S+ohAbZ6AQCaGgz/JyoRAwJNpQIy0SEBoVVpAP7B6QGeCiUBWZFNAZYgrQAjdC0CfWYdAVrSOQIuzf0BoWxxAkI/LPwKv6j84OP4/XJMLQBHkLkBWFcs/prI2QPzgBkA+99o/a0BUP94F4j+HaSFAkGFHQMLJPEDsG3Y/SaljP42DnD/GA9U/QtqXP4BgJD+7PrI/G70zP2tPbz9BSUs/BvlAP+k3/T/TBilA9k6qP/w07z9McQhAf0crQMWBK0A9kD9A+Uc9QLjybUAyy2JANQNOQMzxRUBp3hdAmg1lQCGtekC+54hAv6qFQMdlW0CnmiBAgElTQBntCD+zogq+ICemvp1A5z1fYCW+jgGFvsCvfL38ogi/vbR8vqbKzb7hY2i+dGwuPRZRHUCli0ZAJPNtQBdAYUB0CF9AhQXVPzq+BUBwMIE/uNywPvKdPT8ngThArVkqQCysjT8R7ps/iRpzPxj7vz+PMw0/inbmPkEiMT+RoaA/KRu2P7GLrD8P/gBAzYYGQPx7eECtripATgfzP8EyQ0CoTFFAq9JbQKDieUB0ymxAUnpPQKpsK0DWreg/iJsiQK0dzj+uRAdAYmctQLzBHUAghhhA7yk5QGi0dD6Qt+o+4XsfPwcb+z0ZpfW9VQyFPqUexj4D3KW99Moovnsam77E9V++7JPmPcuYKT9ghrY+oIMOv9Cp776vQeK9HrWBvkepH7+ygFQ+5DvXP8p4FkCMfgw/OUKVP5s9fD+fGhxAwm+4PwXGJkDTcHpAutCFQD/lmkAe5EhAcfBrQMjZgkD0MSVA90ZSQHkdYkD+MqBAYGyiQK4Gm0DS+JFAv3mMQDzFo0CekKdASxOeQL2KlUBkUZFApBx6QNTFjEBISohAkopeQDwKnkBXwqVAdTeiQMbYnUDPAOk/qGPDPw=="},"shape":[181],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[181],"dtype":"float32","order":"little"}],["topic",["Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Others","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Others","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Others","Antiretroviral Therapy","Antiretroviral Therapy Interactions","Antiretroviral Therapy","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy Interactions","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Others","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy","Antiretroviral Therapy"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180]],["content",["ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\nfumarate tablet, film coated \\n \\nGilead Sciences, Inc.\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\neffectively. See full prescribing information for ATRIPLA.\\nATRIPLA\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\nGILEAD ACCESS PROGRAM\\nInitial U.S. Approval: 2006\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...","discontinuation of ATRIPLA. Closely monitor hepatic function with both clinical and\\nlaboratory follow-up for at least several months in patients who are coinfected with\\nHIV-1 and HBV and discontinue ATRIPLA. If appropriate, initiation of anti-hepatitis B\\ntherapy may be warranted. (\\n5.1\\n)\\nRECENT MAJOR CHANGES\\nWarnings and Precautions\\n  Nervous System Symptoms (\\n5.6\\n)\\n10/2019\\n    Immune Reconstitution Syndrome (\\n5.12\\n)\\n10/2019\\nINDICATIONS AND USAGE\\nATRIPLA is a three-drug combination of efavirenz ...","agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. (\\n1\\n)\\nDOSAGE AND ADMINISTRATION\\nTesting: Consult Full Prescribing Information for important testing recommendations prior to initiation\\nand during treatment with ATRIPLA. (\\n2.1\\n)\\nRecommended dosage in adults and pediatric patients weighing at least 40 kg: \\nOne tablet once daily\\ntaken orally on an empty stomach, preferably at bedtime. (\\n2.2\\n)\\nRenal impairment: \\nNot recommended in patients with es...","2.5\\n)\\nDOSAGE FORMS AND STRENGTHS\\nTablets: 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate. (\\n3\\n)\\nCONTRAINDICATIONS\\nPreviously demonstrated hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or\\ntoxic skin eruptions) to efavirenz, a component of ATRIPLA. (\\n4\\n)\\nCoadministration with voriconazole. (\\n4\\n)\\nCoadministration with elbasvir/grazoprevir. (\\n4\\n)\\nWARNINGS AND PRECAUTIONS","WARNINGS AND PRECAUTIONS\\nRash: Discontinue if severe rash develops. (\\n5.2\\n, \\n6.1\\n)\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\noccurred in patients with no pre-existing hepatic disease. (\\n5.3\\n, \\n6.2\\n, \\n8.7\\n)\\nRisk of adverse reactions or loss of ...","in patients at higher risk of Torsade de Pointes. (\\n5.4\\n)\\nSerious psychiatric symptoms: Immediate medical evaluation is recommended. (\\n5.5\\n, \\n6.1\\n)\\nNervous system symptoms (NSS): NSS are frequent, usually begin 1\\u22122 days after initiating therapy,\\nand resolve in 2\\u22124 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset\\nof psychiatric symptoms. (\\n2.2\\n, \\n5.6\\n)\\nNew onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Prior\\nto initiati...","trimester. Avoid pregnancy while receiving ATRIPLA and for 12 weeks after discontinuation. (\\n5.8\\n, \\n8.1\\n)\\nDecreases in bone mineral density (BMD): Consider assessment of BMD in patients with a history of\\npathological fracture or other risk factors for osteoporosis or bone loss. (\\n5.9\\n)\\nConvulsions: Use caution in patients with a history of seizures. (\\n5.10\\n)\\nLactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop\\nsymptoms or laboratory findings suggestiv...","clinical trial of EFV, FTC, and TDF are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia,\\nabnormal dreams, and rash. (\\n6.1\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at\\nsafety_fc@gilead.com or the US FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.\\nDRUG INTERACTIONS\\nConsult Full Prescribing Information prior to and during treatment for important potential drug\\ninteractions. (\\n4\\n, \\n5.4\\n, \\n7\\n)\\nHIV-1 protease inhibitors: \\nCoadministration of ATRIPLA ...","7.3\\n)\\nUSE IN SPECIFIC POPULATIONS\\nPregnancy: \\nAvoid pregnancy while receiving ATRIPLA and for 12 weeks after discontinuation. (\\n5.8\\n, \\n8.3\\n)\\nLactation: Breastfeeding is not recommended. (\\n8.2\\n)\\nFemales and Males of Reproductive Potential: Pregnancy testing and contraception are recommended.\\n(\\n8.3\\n)\\nPediatrics: \\nThe incidence of rash was higher than in adults. (\\n5.2\\n, \\n6.1\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 10/2019\\nFULL PRESCRIBING INFORMATION:...","2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\n2.5 Dosage Adjustment with Rifampin\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\nHBV\\n5.2 Ra...","5.11 Lactic Acidosis/Severe Hepatomegaly with Steatosis\\n5.12 Immune Reconstitution Syndrome\\n5.13 Fat Redistribution\\n6 ADVERSE REACTIONS\\n6.1 Clinical Trials Experience\\n6.2 Postmarketing Experience\\n7 DRUG INTERACTIONS\\n7.1 Efavirenz\\n7.2 Drugs Affecting Renal Function\\n7.3 Established and Potentially Significant Interactions\\n7.4 Efavirenz Assay Interference\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\n8.2 Lactation\\n8.3 Females and Males of Reproductive Potential\\n8.4 Pediatric Use\\n8.5 Geriatric Use\\n8.6...","16 HOW SUPPLIED/STORAGE AND HANDLING\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\nreported in patients who are coinfected with HIV-1 and HBV and have\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\nClosely monitor hepatic function with both clinical and laboratory follow-\\nup f...","agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at\\nleast 40 kg.\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\nPrior to or when initiating ATRIPLA, test patients for hepatitis B virus infection \\n[see\\nWarnings and Precautions (5.1)\\n].\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\nserum creatinine, estimated creatinine clearance, urine glucose and urine protein in all\\n...","childbearing potential \\n[see \\nWarnings and Precautions (5.8)\\n, \\nUse in Specific Populations\\n(8.1\\n, \\n8.3)\\n].\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at\\nLeast 40 kg\\nSections or subsections omitted from the full prescribing information are not listed.","ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\nThe recommended dosage of ATRIPLA in \\nadults and pediatric patients weighing at least\\n40 kg\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\nimprove the tolerability of nervous system symptoms \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...","Impairment\\nATRIPLA is not recommended in patients with moderate to severe hepatic impairment\\n(Child-Pugh B or C) \\n[see \\nWarnings and Precautions (5.3)\\n and \\nUse in Specific Populations\\n(8.7)\\n]\\n.\\n2.5 Dosage Adjustment with Rifampin\\nIf ATRIPLA is co-administered with rifampin in patients weighing 50 kg or more, take one\\ntablet of ATRIPLA once daily followed by one additional 200 mg per day of efavirenz \\n[see\\nDrug Interactions (7.3)\\n and \\nClinical Pharmacology (12.3)\\n]\\n.\\n3 DOSAGE FORMS AND STRENGTH...","4 CONTRAINDICATIONS\\nATRIPLA is contraindicated in patients with previously demonstrated clinically\\nsignificant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme,\\nor toxic skin eruptions) to efavirenz, a component of ATRIPLA [see \\nWarnings and\\nPrecautions (5.2)\\n].\\nATRIPLA is contraindicated to be coadministered with voriconazole or\\nelbasvir/grazoprevir \\n[see \\nDrug Interactions (7.3)\\n and \\nClinical Pharmacology (12.3)\\n].\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Severe Acute Exacerbation ...","closely monitored, with both clinical and laboratory follow-up for at least several months\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\nliver failure.\\n5.2 Rash\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\nexperienced new-onset skin rash co...","EFV in all trials and expanded access was 0.1%. Rashes are usually mild-to-moderate\\nmaculopapular skin eruptions that occur within the first 2 weeks of initiating therapy with\\nEFV (median time to onset of rash in adults was 11 days) and, in most subjects\\ncontinuing therapy with EFV, rash resolves within 1 month (median duration, 16 days).\\nThe discontinuation rate for rash in adult clinical trials was 1.7% (17/1,008). ATRIPLA can\\nbe reinitiated in patients interrupting therapy because of rash. AT...","patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson\\nsyndrome), alternative therapy should be considered \\n[see \\nContraindications (4)\\n]\\n.\\nExperience with EFV in subjects who discontinued other antiretroviral agents of the\\nNNRTI class is limited. Nineteen subjects who discontinued nevirapine because of rash\\nhave been treated with EFV. Nine of these subjects developed mild-to-moderate rash\\nwhile receiving therapy with EFV, and two of these subjects discontinued becaus...","days). Prophylaxis with appropriate antihistamines before initiating therapy with ATRIPLA\\nin pediatric patients should be considered.\\n5.3 Hepatotoxicity\\nPostmarketing cases of hepatitis, including fulminant hepatitis progressing to liver failure\\nrequiring transplantation or resulting in death, have been reported in patients treated\\nwith EFV, a component of ATRIPLA. Reports have included patients with underlying\\nhepatic disease, including coinfection with hepatitis B or C, and patients without pr...","[see \\nDosage and Administration (2.1)\\n].\\n Consider discontinuing ATRIPLA in patients with\\npersistent elevations of serum transaminases to greater than five times the upper limit\\nof the normal range.\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\nsigns or symptoms of hepatitis or hepatic decompensation \\n[see \\nAdverse Reactions\\n(6.1)\\n].\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\nInteractions\\nThe concomitant use of ATRIPLA and other d...","concomitant drug.\\nQTc prolongation has been observed with the use of EFV \\n[see \\nDrug Interactions (7.1)\\nand \\nClinical Pharmacology (12.2)\\n]\\n. Consider alternatives to ATRIPLA when\\ncoadministered with a drug with a known risk of Torsade de Pointes or when\\nadministered to patients at higher risk of Torsade de Pointes.\\nSee \\nTable 3\\n for steps to prevent or manage these possible and known significant drug\\ninteractions, including dosing recommendations. Consider the potential for drug\\ninteractions pr...","EFV, a component of ATRIPLA. In controlled trials of 1,008 subjects treated with\\nregimens containing EFV for a mean of 2.1 years and 635 subjects treated with control\\nregimens for a mean of 1.5 years, the frequency (regardless of causality) of specific\\nserious psychiatric events among subjects who received EFV or control regimens,\\nrespectively, were: severe depression (2.4%, 0.9%), suicidal ideation (0.7%, 0.3%),\\nnonfatal suicide attempts (0.5%, 0%), aggressive behavior (0.4%, 0.5%), paranoid\\nre...","follow-up 180 weeks, 102 weeks, and 76 weeks for subjects treated with EFV +\\nzidovudine + lamivudine, EFV + indinavir, and indinavir + zidovudine + lamivudine,\\nrespectively), treatment with EFV was associated with an increase in the occurrence of\\nthese selected psychiatric symptoms. Other factors associated with an increase in the\\noccurrence of these psychiatric symptoms were history of injection drug use,\\npsychiatric history, and receipt of psychiatric medication at trial entry; similar\\nassocia...","discontinued or interrupted treatment because of one or more of these selected\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\nhave also been reported and may be associated with increased EFV exposure. Patients\\nwith serious psychiatric adverse experiences should seek immediate medical ev...","central nervous system symptoms (any grade, regardless of causality) compared to\\n25% (156/635) of subjects receiving control regimens. These symptoms included\\ndizziness (28.1% of the 1,008 subjects), insomnia (16.3%), impaired concentration\\n(8.3%), somnolence (7.0%), abnormal dreams (6.2%), and hallucinations (1.2%). Other\\nreported symptoms were euphoria, confusion, agitation, amnesia, stupor, abnormal\\nthinking, and depersonalization. The majority of these symptoms were mild to moderate\\n(50.7%);...","severity ranged from 5% to 9% in subjects treated with regimens containing EFV and\\nfrom 3% to 5% in subjects treated with a control regimen. Patients should be informed\\nthat these common symptoms were likely to improve with continued therapy and were\\nnot predictive of subsequent onset of the less frequent psychiatric symptoms \\n[see\\nWarnings and Precautions (5.5)\\n]\\n. Dosing at bedtime may improve the tolerability of these\\nnervous system symptoms \\n[see \\nDosage and Administration (2.2)\\n]\\n.\\nAnalysis...","confusion, psychomotor slowing, psychosis, delirium), may occur months to years after\\nbeginning EFV therapy. Some events of late-onset neurotoxicity have occurred in\\npatients with CYP2B6 genetic polymorphisms which are associated with increased EFV\\nlevels despite standard dosing of EFV. Patients presenting with signs and symptoms of\\nserious neurologic adverse experiences should be evaluated promptly to assess the\\npossibility that these events may be related to EFV use, and whether discontinuatio...","concentration, and/or drowsiness should avoid potentially hazardous tasks such as\\ndriving or operating machinery.\\n5.7 New Onset or Worsening Renal Impairment\\nEmtricitabine and tenofovir are principally eliminated by the kidney; however, EFV is not.","Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\ncomponent of ATRIPLA \\n[see \\nAdverse Reactions (6.2)\\n].\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\nATRIPLA is...","[see \\nDrug\\nInteractions (7.2)\\n]\\n. Cases of acute renal failure after initiation of high-dose or multiple\\nNSAIDs have been reported in HIV-infected patients with risk factors for renal\\ndysfunction who appeared stable on TDF. Some patients required hospitalization and\\nrenal replacement therapy. Alternatives to NSAIDs should be considered, if needed, in\\npatients at risk for renal dysfunction.\\nPersistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain\\nor weakness may be ...","5.8 Embryo-Fetal Toxicity\\nEfavirenz may cause fetal harm when administered during the first trimester of\\npregnancy. Advise adults and adolescents of childbearing potential who are receiving\\nATRIPLA to avoid pregnancy while receiving ATRIPLA and for 12 weeks after\\ndiscontinuation \\n[see \\nDosage and Administration (2.1)\\n, \\nUse in Specific Populations (8.1\\n,\\n8.3)\\n]\\n.\\n5.9 Bone Loss and Mineralization Defects\\nBone Mineral Density\\nIn clinical trials in HIV-1 infected adults, TDF (a component of ATRIPLA...","Clinical trials evaluating TDF in pediatric and adolescent subjects were conducted. Under\\nnormal circumstances, BMD increases rapidly in pediatric patients. In HIV-1 infected\\nsubjects aged 2 years to less than 18 years, bone effects were similar to those\\nobserved in adult subjects and suggest increased bone turnover. Total body BMD gain\\nwas less in the TDF treated HIV-1 infected pediatric subjects as compared to the control\\ngroups. Similar trends were observed in chronic hepatitis B infected ado...","considered for adult and pediatric patients who have a history of pathologic bone\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\nconsultation should be obtained.\\nMineralization Defects\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\npain or pain in extre...","be considered in patients at risk of renal dysfunction who present with persistent or\\nworsening bone or muscle symptoms while receiving TDF-containing products \\n[see\\nWarnings and Precautions (5.7)\\n].\\n5.10 Convulsions\\nConvulsions have been observed in adult and pediatric patients receiving EFV, generally\\nin the presence of known medical history of seizures. Caution must be taken in any\\npatient with a history of seizures.\\nPatients who are receiving concomitant anticonvulsant medications primarily ...","reported with the use of nucleoside analogs, including TDF and FTC, components of\\nATRIPLA, alone or in combination with other antiretrovirals. Treatment with ATRIPLA\\nshould be suspended in any patient who develops clinical or laboratory findings\\nsuggestive of lactic acidosis or pronounced hepatotoxicity (which may include\\nhepatomegaly and steatosis even in the absence of marked transaminase elevations).\\n5.12 Immune Reconstitution Syndrome\\nImmune reconstitution syndrome has been reported in patie...","infections (such as \\nMycobacterium avium\\n infection, cytomegalovirus, \\nPneumocystis\\njirovecii\\n pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and\\ntreatment.\\nAutoimmune disorders (such as Graves&#x27; disease, polymyositis, Guillain-Barr\\u00e9 syndrome,\\nand autoimmune hepatitis) have also been reported to occur in the setting of immune\\nreconstitution; however, the time to onset is more variable, and can occur many months\\nafter initiation of treatment.\\n5.13 Fat Redistribution\\nRe...","enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\n\\"cushingoid appearance,\\" has been observed in patients receiving antiretroviral therapy,\\nincluding EFV. The mechanism and long-term consequences of these events are\\ncurrently unknown. A causal relationship has not been established.\\n6 ADVERSE REACTIONS\\nThe following adverse reactions are discussed in other sections of the labeling:\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...","[see \\nWarnings and Precautions (5.7)\\n].\\nEmbryo-Fetal Toxicity \\n[see \\nWarnings and Precautions (5.8)\\n]\\n.\\nBone Loss and Mineralization Defects \\n[see \\nWarnings and Precautions (5.9)\\n].\\nConvulsions \\n[see \\nWarnings and Precautions (5.10)\\n]\\n.\\nLactic Acidosis/Severe Hepatomegaly with Steatosis \\n[see \\nWarnings and Precautions\\n(5.11)\\n]\\n.\\nImmune Reconstitution Syndrome \\n[see \\nWarnings and Precautions (5.12)\\n].\\nFat Redistribution \\n[see \\nWarnings and Precautions (5.13)\\n].\\n6.1 Clinical Trials Experience\\nBeca...","Study 934 was an open-label active-controlled trial in which 511 antiretroviral-na\\u00efve\\nsubjects received either FTC + TDF administered in combination with EFV (N=257) or\\nzidovudine (AZT)/lamivudine (3TC) administered in combination with EFV (N=254).\\nThe most common adverse reactions (incidence greater than or equal to 10%, any\\nseverity) occurring in Study 934 include diarrhea, nausea, fatigue, headache, dizziness,\\ndepression, insomnia, abnormal dreams, and rash. Adverse reactions observed in Stud...","*\\n\\u2020\\n\\u2021\\nDizziness\\n8%\\n7%\\nUpper respiratory tract infections\\n8%\\n5%\\nSinusitis\\n8%\\n4%\\nRash Event\\n7%\\n9%\\nHeadache\\n6%\\n5%\\nInsomnia\\n5%\\n7%\\nAnxiety\\n5%\\n4%\\nNasopharyngitis\\n5%\\n3%\\nVomiting\\n2%\\n5%\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\nconsistent with those seen in Study 934 and those seen with the individ...","antiretroviral agents.\\nEfavirenz:\\n \\nThe most significant adverse reactions observed in subjects treated with EFV\\nwere nervous system symptoms \\n[see \\nWarnings and Precautions (5.6)\\n],\\n psychiatric\\nsymptoms \\n[see \\nWarnings and Precautions (5.5)\\n],\\n and rash \\n[see \\nWarnings and\\nPrecautions (5.2)\\n]\\n.\\nSelected adverse reactions of moderate-to-severe intensity observed in greater than or\\nequal to 2% of EFV-treated subjects in two controlled clinical trials included pain,\\nimpaired concentration, abnorm...","significantly higher number of subjects treated with EFV 600 mg than in control\\nsubjects.\\nSkin discoloration has been reported with higher frequency among FTC-treated subjects;\\nit was manifested by hyperpigmentation on the palms and/or soles and was generally\\nmild and asymptomatic. The mechanism and clinical significance are unknown.\\nClinical Trials in Pediatric Subjects\\nEfavirenz:\\n \\nAssessment of adverse reactions is based on three pediatric clinical trials in\\n182 HIV-1 infected pediatric subje...","Frequencies of adverse reactions are based on all treatment-emergent adverse events,\\nregardless of relationship to study drug.\\nFrom Weeks 96 to 144 of the trial, subjects received FTC/TDF administered in combination with\\nEFV in place of FTC + TDF with EFV.\\nRash event includes rash, exfoliative rash, rash generalized, rash macular, rash maculopapular,\\nrash pruritic, and rash vesicular.\\n\\u2021","exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\n[see \\nWarnings\\nand Precautions (5.2)\\n]\\n.\\nEmtricitabine:\\n \\nIn addition to the adverse reactions reported in adults, anemia and\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\nwho received treatment with FTC in the larger of ...","[see\\nWarnings and Precautions (5.9)\\n]\\n.\\nLaboratory Abnormalities\\nEfavirenz, Emtricitabine and Tenofovir DF:\\n Laboratory abnormalities observed in Study\\n934 were generally consistent with those seen in previous trials (Table 2).\\nTable 2 \\nSignificant Laboratory Abnormalities Reported in \\u22651% of Subjects in\\nEither Treatment Group in Study 934 (0\\u2013144 Weeks)\\nFTC+TDF+EFV\\nAZT/3TC+EFV\\nN=257\\nN=254\\n*\\nAny \\u2265 Grade 3 Laboratory\\nAbnormality\\n30%\\n26%\\nFasting Cholesterol (&gt;240 mg/dL)\\n22%\\n24%\\nCreatine Kinase\\n(M: &gt;...","&lt;1%\\n1%\\nNeutrophils (&lt;750/mm\\n)\\n3%\\n5%\\nFasting Triglycerides (&gt;750 mg/dL)\\n4%\\n2%\\nLaboratory abnormalities observed in Study 073 were generally consistent with those in\\nStudy 934.\\nHepatic Events:\\n \\nIn Study 934, 19 subjects treated with EFV, FTC, and TDF and 20\\n*\\nFrom Weeks 96 to 144 of the trial, subjects received FTC/TDF administered in combination with\\nEFV in place of FTC + TDF with EFV.\\n3","subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...","or establish a causal relationship to drug exposure.\\nEfavirenz:\\nCardiac Disorders\\n \\nPalpitations\\nEar and Labyrinth Disorders\\n \\nTinnitus, vertigo\\nEndocrine Disorders\\n \\nGynecomastia\\nEye Disorders\\n \\nAbnormal vision\\nGastrointestinal Disorders\\n \\nConstipation, malabsorption\\nGeneral Disorders and Administration Site Conditions\\n \\nAsthenia\\nHepatobiliary Disorders\\n \\nHepatic enzyme increase, hepatic failure, hepatitis\\nImmune System Disorders\\n \\nAllergic reactions\\nMetabolism and Nutrition Disorders\\n \\nRedistr...","disturbances, convulsions, hypoesthesia, paresthesia, neuropathy, tremor\\nPsychiatric Disorders\\n \\nAggressive reactions, agitation, delusions, emotional lability, mania, neurosis, paranoia,\\npsychosis, suicide, catatonia\\nRespiratory, Thoracic and Mediastinal Disorders","Dyspnea\\nSkin and Subcutaneous Tissue Disorders\\n \\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\nEmtricitabine\\n:\\n No postmarketing adverse reactions have been identified for inclusion in\\nthis section.\\nTenofovir DF:\\nImmune System Disorders\\n \\nAllergic reaction, including angioedema\\nMetabolism and Nutrition Disorders\\n \\nLactic acidosis, hypokalemia, hypophosphatemia\\nRespiratory, Thoracic, and Mediastinal Disorders\\n \\nDyspnea\\nGastrointestinal Disorders\\n \\nPancreatitis,...","fractures), muscular weakness, myopathy\\nRenal and Urinary Disorders\\n \\nAcute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal\\nrenal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes\\ninsipidus, renal insufficiency, increased creatinine, proteinuria, polyuria\\nGeneral Disorders and Administration Site Conditions\\n \\nAsthenia\\nThe following adverse reactions, listed under the body system headings above, may\\noccur as a consequence of proxima...","are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when\\ncoadministered with EFV.\\nDrugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be\\nexpected to increase the clearance of EFV, resulting in lowered plasma concentrations\\n[see \\nDosage and Administration (2.2)\\n]\\n.","There is limited information available on the potential for a pharmacodynamic interaction\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\nobserved with the use of EFV \\n[see \\nClinical Pharmacology (12.2)\\n].\\n Consider alternatives to\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\n7.2 Drugs Affecting Renal Function\\nFTC and tenofovir are primarily eliminated by the kidneys\\n[see \\nClinical Pharmacology\\n(12.3)\\n].\\n Coadministration of ATRI...","high-dose or multiple NSAIDs \\n[see \\nWarnings and Precautions (5.7)\\n]\\n. Drugs that decrease\\nrenal function may increase concentrations of FTC and/or tenofovir.\\n7.3 Established and Potentially Significant Interactions\\nOther important drug interaction information for ATRIPLA is summarized in Table 3. The\\ndrug interactions described are based on trials conducted with either ATRIPLA, the\\ncomponents of ATRIPLA (EFV, FTC, or TDF) as individual agents, or are potential drug\\ninteractions \\n[see \\nClinical ...","combined effect of EFV plus TDF on\\natazanavir plasma concentrations is not\\nknown. There are insufficient data to\\nsupport dosing recommendations for\\natazanavir or atazanavir/ritonavir in\\ncombination with ATRIPLA.\\nProtease inhibitor:\\n  fosamprenavir\\n  calcium\\n\\u2193 amprenavir\\nFosamprenavir (unboosted): Appropriate\\ndoses of fosamprenavir and ATRIPLA\\nwith respect to safety and efficacy have\\nnot been established.\\nFosamprenavir/ritonavir: An additional\\n100 mg/day (300 mg total) of ritonavir is\\nrecommended...","the increased indinavir metabolism due to\\nEFV.\\nProtease inhibitor:\\n  darunavir/ritonavir\\n\\u2191 tenofovir\\nMonitor patients receiving ATRIPLA\\nconcomitantly with ritonavir-boosted\\ndarunavir for TDF-associated adverse\\nreactions. Discontinue ATRIPLA in\\npatients who develop TDF-associated\\nadverse reactions.\\n  lopinavir/ritonavir\\n\\u2193 lopinavir\\n\\u2191 tenofovir\\nDo not use once daily administration of\\nlopinavir/ritonavir. Dose increase of\\nlopinavir/ritonavir is recommended for all\\npatients when coadministered with ...","reactions\\nProtease inhibitor:\\n  ritonavir\\n\\u2191 ritonavir\\n\\u2191 efavirenz\\nWhen ritonavir 500 mg every 12 hours\\nwas coadministered with EFV 600 mg\\nonce daily, the combination was\\nassociated with a higher frequency of\\nadverse clinical experiences (e.g.,\\ndizziness, nausea, paresthesia) and\\nlaboratory abnormalities (elevated liver\\nenzymes). Monitoring of liver enzymes is\\nrecommended when ATRIPLA is used in\\ncombination with ritonavir.\\nProtease inhibitor:\\n  saquinavir\\n\\u2193 saquinavir\\nAppropriate doses of the com...","didanosine should be monitored closely\\nfor didanosine-associated adverse\\nreactions. Discontinue didanosine in\\npatients who develop didanosine-\\nassociated adverse reactions. Higher\\ndidanosine concentrations could\\npotentiate didanosine-associated adverse\\nreactions, including pancreatitis, and\\nneuropathy. Suppression of CD4+ cell\\ncounts has been observed in patients","NRTI:\\n  didanosine\\n\\u2191 didanosine\\nreceiving TDF with didanosine 400 mg\\ndaily. \\nIn patients weighing greater than 60 kg,\\nreduce the didanosine dose to 250 mg\\nwhen it is coadministered with ATRIPLA.\\nIn patients weighing less than 60 kg,\\nreduce the didanosine dose to 200 mg\\nwhen it is coadministered with ATRIPLA.\\nWhen coadministered, ATRIPLA and\\nVidex EC may be taken under fasted\\nconditions or with a light meal (less than\\n400 kcal, 20% fat).\\nNNRTI:\\n  Other NNRTIs\\n\\u2191 or \\u2193 efavirenz\\nand/or NNRTI\\nCombini...","\\u2193 boceprevir\\nPlasma trough concentrations of\\nboceprevir were decreased when\\nboceprevir was coadministered with EFV,\\nwhich may result in loss of therapeutic\\neffect. The combination should be\\navoided.\\n  elbasvir/grazoprevir\\n\\u2193 elbasvir\\n\\u2193 grazoprevir\\nCoadministration of ATRIPLA with\\nelbasvir/grazoprevir is contraindicated\\n[see \\nContraindications (4)\\n]\\n because it\\nmay lead to loss of virologic response to\\nelbasvir/grazoprevir.\\n  glecaprevir/pibrentasvir\\n\\u2193 glecaprevir\\n\\u2193 pibrentasvir\\nCoadministration o...","simeprevir\\n\\u2193 simeprevir\\n\\u2194 efavirenz\\nConcomitant administration of simeprevir\\nwith EFV is not recommended because it\\nmay result in loss of therapeutic effect of\\nsimeprevir.\\n  sofosbuvir/velpatasvir\\n  sofosbuvir/velpatasvir/\\nvoxilaprevir\\n\\u2191 tenofovir\\n\\u2193 velpatasvir\\n\\u2193 voxilaprevir\\nCoadministration of EFV-containing\\nregimens and EPCLUSA\\u2122\\n(sofosbuvir/velpatasvir) or VOSEVI\\u2122\\n(sofosbuvir/velpatasvir/voxilaprevir) is\\nnot recommended.\\nOther agents","Anticoagulant:\\n  warfarin\\n\\u2191 or \\u2193 warfarin\\nPlasma concentrations and effects\\npotentially increased or decreased by\\nEFV.\\nAnticonvulsants:\\n  carbamazepine\\n\\u2193 carbamazepine\\n\\u2193 efavirenz\\nThere are insufficient data to make a\\ndose recommendation for ATRIPLA.\\nAlternative anticonvulsant treatment\\nshould be used.\\n  phenytoin\\n  phenobarbital\\n\\u2193 anticonvulsant\\n\\u2193 efavirenz\\nPotential for reduction in anticonvulsant\\nand/or EFV plasma levels; periodic\\nmonitoring of anticonvulsant plasma\\nlevels should be conducted...","sertraline\\n\\u2193 sertraline\\nIncreases in sertraline dose should be\\nguided by clinical response.\\nAntifungals:\\n  itraconazole\\n\\u2193 itraconazole\\n\\u2193 hydroxy-\\nitraconazole\\nSince no dose recommendation for\\nitraconazole can be made, alternative\\nantifungal treatment should be\\nconsidered.\\n  ketoconazole\\n\\u2193 ketoconazole\\nDrug interaction trials with ATRIPLA and\\nketoconazole have not been conducted.\\nEfavirenz has the potential to decrease\\nplasma concentrations of ketoconazole.\\n  posaconazole\\n\\u2193 posaconazole\\nAvoid con...","Anti-infective:\\n  clarithromycin\\n\\u2193 clarithromycin\\n\\u2191 14-OH metabolite\\nConsider alternatives to macrolide\\nantibiotics because of the risk of QT\\ninterval prolongation.\\nAntimycobacterial:\\n  rifabutin\\n\\u2193 rifabutin\\nIncrease daily dose of rifabutin by 50%.\\nConsider doubling the rifabutin dose in\\nregimens where rifabutin is given 2 or 3\\ntimes a week.\\n  rifampin\\n\\u2193 efavirenz\\nIf ATRIPLA is coadministered with\\nrifampin to patients weighing 50 kg or\\nmore, an additional 200 mg/day of EFV is\\nrecommended.\\nAntima...","artemether/lumefantrine\\n  atovaquone/proquanil\\n\\u2193 dihydroartemisinin\\n\\u2193 lumefantrine\\n\\u2193 atovaquone\\n\\u2193 proguanil\\nrisk of QT interval prolongation \\n[see\\nWarnings and Precautions (5.4)\\n]\\n.\\nConcomitant administration of\\natovaquone/proguanil with ATRIPLA is\\nnot recommended.\\nCalcium channel\\nblockers:\\n  diltiazem\\n\\u2193 diltiazem\\n\\u2193 desacetyl\\ndiltiazem\\n\\u2193 N-monodes-\\nmethyl diltiazem\\nDiltiazem dose adjustments should be\\nguided by clinical response (refer to the\\nfull prescribing information for diltiazem).\\nNo dose ...","CYP3A. The potential exists for reduction\\nin plasma concentrations of the calcium\\nchannel blocker. Dose adjustments\\nshould be guided by clinical response\\n(refer to the full prescribing information\\nfor the calcium channel blocker).\\nHMG-CoA reductase\\ninhibitors:\\n  atorvastatin\\n  pravastatin\\n  simvastatin\\n\\u2193 atorvastatin\\n\\u2193 pravastatin\\n\\u2193 simvastatin\\nPlasma concentrations of atorvastatin,\\npravastatin, and simvastatin decreased\\nwith EFV. Consult the Full Prescribing\\nInformation for the HMG-CoA reductas...","concentrations, but progestin levels\\n(norelgestromin and levonorgestrel) were\\nmarkedly decreased. No effect of ethinyl\\nestradiol/norgestimate on EFV plasma\\nconcentrations was observed.\\nImplant:\\n  etonogestrel\\n\\u2193 etonogestrel\\nA reliable method of barrier\\ncontraception must be used in addition\\nto hormonal contraceptives. Decreased\\nexposure of etonogestrel may be\\nexpected. There have been\\npostmarketing reports of contraceptive\\nfailure with etonogestrel in EFV-exposed\\npatients.\\nImmunosuppressants:\\n  ...","*\\ntacrolimus, sirolimus, and\\nothers metabolized by\\nCYP3A\\nsuppressant\\nmay be required. Close monitoring of\\nimmunosuppressant concentrations for\\nat least 2 weeks (until stable\\nconcentrations are reached) is\\nrecommended when starting or stopping\\ntreatment with ATRIPLA.\\nNarcotic analgesic:\\n  methadone\\n\\u2193 methadone\\nCoadministration of EFV in HIV-1 infected\\nindividuals with a history of injection drug\\nuse resulted in signs of opiate\\nwithdrawal. Methadone dose was\\nincreased by a mean of 22% to alleviate...","positive urine cannabinoid test results have been reported with some screening assays\\nin uninfected and HIV-infected subjects receiving EFV. Confirmation of positive screening\\ntests for cannabinoids by a more specific method is recommended.\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nAntiretroviral Pregnancy Registry\\nThere is a pregnancy exposure registry that monitors pregnancy outcomes in adults\\nand adolescents exposed to ATRIPLA during pregnancy. Healthcare providers are\\nencouraged to registe...","Prospective pregnancy data from the APR are not sufficient to adequately assess this\\nrisk. Although a causal relationship has not been established between exposure to EFV\\nin the first trimester and neural tube defects, similar malformations have been observed\\nin studies conducted in monkeys at doses similar to the human dose \\n(see \\nData\\n)\\n. In\\naddition, fetal and embryonic toxicities occurred in rats at a dose 10 times less than the\\nhuman exposure at the recommended clinical human dose (RHD) of ...","for EFV, FTC, or TDF compared with the background rate for major birth defects of\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\nProgram (MACDP) \\n(see \\nData\\n)\\n.\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\nThe background risk of major birth defects and miscarriage for the indicated population\\nis unknown. The APR uses the MACDP as t...","FTC and TDF were administered separately at doses/exposures \\u226560 (FTC), \\u226514 (TDF)\\nand 2.7 (tenofovir) times those at the RHD of ATRIPLA (\\nsee \\nData\\n).\\nData\\nHuman Data\\nEfavirenz:\\n There are retrospective postmarketing reports of findings consistent with\\nneural tube defects, including meningomyelocele, all in infants of mothers exposed to\\nEFV-containing regimens in the first trimester.\\nBased on prospective reports to the APR of 1,217 exposures to EFV-containing\\nregimens during pregnancy resulting i...","defects in live births was 2.3% (95% CI: 1.5% to 3.5%) with first trimester exposure to\\nEFV-containing regimens, and 1.5% (95% CI: 0.3% to 4.5%) with the second/third\\ntrimester exposure to EFV-containing regimens. One of these prospectively reported\\ndefects with first-trimester exposure was a neural tube defect. A single case of\\nanophthalmia with first-trimester exposure to EFV has also been prospectively reported.\\nThis case also included severe oblique facial clefts and amniotic banding, which ...","increase in overall major birth defects with FTC compared with the background birth\\ndefect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of\\nbirth defects in live births was 2.4% (95% CI: 1.9% to 3.1%) with first trimester\\nexposure to FTC-containing regimens and 2.3% (95% CI: 1.5% to 3.3%) with the\\nsecond/third trimester exposure to FTC-containing regimens.\\nTenofovir DF:\\n Based on prospective reports from the APR of 5,105 exposures to TDF-\\ncontaining regimens during p...","birth defects in live births was 2.3% (95% CI: 1.8% to 2.9%) with first trimester\\nexposure to TDF-containing regimens, and 2.2% (95% CI: 1.6% to 3.1%) with the\\nsecond/third trimester exposure to TDF-containing regimens.","Animal Data\\nEfavirenz:\\n Effects of EFV on embryo-fetal development have been studied in three\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...","established for this study because only one dosage was evaluated. In rats, EFV was\\nadministered either during organogenesis (gestation Days 7 to 18) or from gestation\\nDay 7 through lactation Day 21 at 50, 100, or 200 mg/kg/day. Administration of 200\\nmg/kg/day in rats was associated with an increase in the incidence of early resorptions,\\nand doses 100 mg/kg/day and greater were associated with early neonatal mortality. The\\nAUC at the NOAEL (50 mg/kg/day) in this rat study was 0.1 times that in hu...","mg/kg/day) in rabbits was 0.4 times that in humans at the RHD.\\nEmtricitabine:\\n FTC was administered orally to pregnant mice (at 0, 250, 500, or 1,000\\nmg/kg/day), and rabbits (at 0, 100, 300, or 1,000 mg/kg/day) through organogenesis\\n(on gestation days 6 through 15, and 7 through 19, respectively). No significant\\ntoxicological effects were observed in embryo-fetal toxicity studies performed with FTC\\nin mice at exposures (AUC) approximately 60 times higher and in rabbits at\\napproximately 120 times...","(AUC) of approximately 60 times higher than human exposures at the RHD.\\nTenofovir DF:\\n TDF was administered orally to pregnant rats (at 0, 50, 150, or 450\\nmg/kg/day) and rabbits (at 0, 30, 100, or 300 mg/kg/day) through organogenesis (on\\ngestation days 7 through 17, and 6 through 18, respectively). No significant\\ntoxicological effects were observed in embryo-fetal toxicity studies performed with TDF\\nin rats at doses up to 14 times the RHD based on body surface area comparisons and in\\nrabbits at ...","tenofovir exposures of approximately 2.7 times higher than human exposures at the\\nRHD.\\n8.2 Lactation\\nRisk Summary\\nThe Centers for Disease Control and Prevention recommend that HIV-1 infected\\nmothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. \\n.","Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\nin human breast milk.\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\nbreastfeed if they are receiving ATRIPLA....","]\\n.\\nContraception\\nAdvise adults and adolescents of childbearing potential to use effective contraception\\nduring treatment with ATRIPLA and for 12 weeks after discontinuing ATRIPLA due to the\\nlong half-life of EFV, a component of ATRIPLA. Hormonal methods that contain\\nprogesterone may have decreased effectiveness Always use barrier contraception in\\ncombination with other methods of contraception \\n[see \\nDrug Interactions (7.1\\n, \\n7.3)\\n]\\n.\\n8.4 Pediatric Use\\nThe effectiveness and safety of ATRIPLA as...","infection and data from pediatric studies of the individual components of ATRIPLA (EFV,\\nFTC, and TDF).\\nATRIPLA should only be administered to pediatric patients with a body weight greater\\nthan or equal to 40 kg. Because ATRIPLA is a fixed-dose combination tablet, the dose of\\nATRIPLA cannot be adjusted for patients of lower weight \\n[see \\nWarnings and Precautions\\n(5.2\\n, \\n5.9)\\n, \\nAdverse Reactions (6.1)\\n, and \\nClinical Pharmacology (12.3)\\n].\\n8.5 Geriatric Use\\nClinical trials of EFV, FTC, or TDF did...","disease or other drug therapy.\\n8.6 Renal Impairment\\nBecause ATRIPLA is a fixed-dose combination, and cannot be dose adjusted, it is not\\nrecommended in patients with moderate or severe renal impairment (estimated\\ncreatinine clearance below 50 mL/min) \\n[see \\nDosage and Administration (2.3)\\n, \\nWarnings\\nand Precautions (5.7)\\n].","8.7 Hepatic Impairment\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\nin patients with hepatic impairment, caution should be exercised in administering\\nATRIPLA to these patients \\n[see \\nDosage and Administra...","FTC and TDF (refer to detailed information below), but is unlikely to significantly remove\\nEFV from the blood.\\nEfavirenz:\\n \\nSome patients accidentally taking 600 mg twice daily have reported increased\\nnervous system symptoms. One patient experienced involuntary muscle contractions.\\nEmtricitabine:\\n Hemodialysis treatment removes approximately 30% of the FTC dose over\\na 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400\\nmL/min and a dialysate flow rate of 600 mL...","hemodialysis session removed approximately 10% of the administered tenofovir dose.\\n11 DESCRIPTION\\nATRIPLA is a fixed-dose combination tablet containing EFV, FTC, and TDF. EFV is a non-\\nnucleoside reverse transcriptase inhibitor (NNRTI). FTC is a synthetic nucleoside analog\\nof cytidine. TDF, which is converted \\nin vivo\\n to tenofovir, is an acyclic nucleoside\\nphosphonate (nucleotide) analog of adenosine 5\\u2032-monophosphate.\\nATRIPLA tablets are for oral administration. Each tablet contains 600 mg of E...","polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.\\nEfavirenz:\\n EFV is chemically described as (\\nS\\n)-6-chloro-4-(cyclopropylethynyl)-1,4-\\ndihydro-4-(trifluoromethyl)-2\\nH\\n-3,1-benzoxazin-2-one. Its molecular formula is\\nC\\nH\\nClF\\nNO\\n and its structural formula is:\\n14\\n9\\n3\\n2","Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\nis practically insoluble in water (less than 10 \\u00b5g/mL).\\nEmtricitabine:\\n The chemical name of FTC is 5-fluoro-1-(2\\nR\\n,5\\nS\\n)-[2-(hydroxymethyl)-1,3-\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\nIt has a molecular formula of C\\nH\\nFN\\nO\\nS and a molecular weight of 247.24. It has the\\nfollo...","R\\n)-\\n2[[bis[[(isopropoxycarbonyl)oxy]- methoxy]phosphinyl]methoxy]propyl]adenine\\nfumarate (1:1). It has a molecular formula of C\\nH\\nN\\nO\\nP \\u2219 C\\nH\\nO\\n and a molecular\\nweight of 635.52. It has the following structural formula:\\nTDF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at\\n25 \\u00b0C.\\n12 CLINICAL PHARMACOLOGY\\n8\\n10\\n3\\n3\\n19\\n30\\n5\\n10\\n4\\n4\\n4","12.1 Mechanism of Action\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\n[see\\nMicrobiology (12.4)\\n].\\n12.2 Pharmacodynamics\\nCardiac Electrophysiology\\nEfavirenz:\\n \\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\n of EFV in\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...","CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days\\n[see \\nWarnings and Precautions (5.4)\\n].\\n12.3 Pharmacokinetics\\nATRIPLA:\\n \\nOne ATRIPLA tablet is bioequivalent to one Sustiva or Stocrin tablet (600 mg)\\nplus one EMTRIVA\\u2122 capsule (200 mg) plus one VIREAD\\u2122 tablet (300 mg) following\\nsingle-dose administration to fasting healthy subjects (N=45).\\nEfavirenz:\\n \\nIn HIV-1 infected subjects time-to-peak plasma concentrations were\\napproximately 3\\u20135 hours and steady-state plas...","predominantly albumin. Following administration of \\nC-labeled EFV, 14\\u201334% of the dose\\nwas recovered in the urine (mostly as metabolites) and 16\\u201361% was recovered in feces\\n(mostly as parent drug). In vitro studies suggest CYP3A and CYP2B6 are the major\\nisozymes responsible for EFV metabolism. EFV has been shown to induce CYP enzymes,\\nresulting in induction of its own metabolism. EFV has a terminal half-life of 52\\u201376 hours\\nafter single doses and 40\\u201355 hours after multiple doses.\\nEmtricitabine:\\n \\nF...","\\u00b1 3.1 \\u00b5g\\u2219hr/mL. The mean steady state plasma trough concentration at 24 hours\\npostdose was 0.09 \\u00b5g/mL. The mean absolute bioavailability of FTC was 93%. Less than\\n4% of FTC binds to human plasma proteins \\nin vitro\\n and the binding is independent of\\nconcentration over the range of 0.02\\u2013200 \\u00b5g/mL. Following administration of\\nradiolabelled FTC, approximately 86% is recovered in the urine and 13% is recovered as\\nmetabolites. The metabolites of FTC include 3\\u2032-sulfoxide diastereomers and their\\nglucuro...","Tenofovir DF:\\n \\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\ninfected subjects in the fasted state, maximum serum concentrations (C\\n) were\\nachieved in 1.0 \\u00b1 0.4 hrs (mean \\u00b1 SD) and C\\n and AUC values were 296 \\u00b1 90 ng/mL\\nand 2287 \\u00b1 685 ng\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...","normal renal function of 243 \\u00b1 33 mL/min (mean \\u00b1 SD). Following a single oral dose, the\\nterminal elimination half-life of tenofovir is approximately 17 hours.\\nEffects of Food on Oral Absorption\\nATRIPLA has not been evaluated in the presence of food. Administration of EFV tablets\\nwith a high-fat meal increased the mean AUC and C\\n of EFV by 28% and 79%,\\nrespectively, compared to administration in the fasted state. Compared to fasted\\nadministration, dosing of TDF and FTC in combination with either ...","among the racial groups studied.\\nEmtricitabine:\\n No pharmacokinetic differences due to race have been identified following\\nthe administration of FTC.\\nTenofovir DF:\\n There were insufficient numbers from racial and ethnic groups other than\\nCaucasian to adequately determine potential pharmacokinetic differences among these\\npopulations following the administration of TDF.\\nGender\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\n \\nEFV, FTC, and tenofovir pharmacokinetics are\\nsimilar in male and female subj...","weighing &gt;40 kg, receiving the 600 mg dose of EFV, C\\n was 6.57 \\u03bcg/mL, C\\n was\\n2.82 \\u03bcg/mL, and AUC\\n was 254.78 \\u03bcM\\u2219hr.\\nEmtricitabine:\\n \\nThe pharmacokinetics of FTC at steady state were determined in 27 HIV-1-\\ninfected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg/kg up to\\na maximum dose of 240 mg oral solution or a 200 mg capsule; 26 of 27 subjects in this\\nage group received the 200 mg capsule. Mean \\u00b1 SD C\\n and AUC were 2.7 \\u00b1 0.9\\n\\u03bcg/mL and 12.6 \\u00b1 5.4 \\u03bcg\\u2219hr/mL, respectively...","daily dose of 200 mg.\\nTenofovir DF:\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\ninfected pediatric subjects (12 to less than 18 years). Mean \\u00b1 SD C\\n and AUC\\n are\\n0.38 \\u00b1 0.13 \\u03bcg/mL and 3.39 \\u00b1 1.22 \\u03bcg\\u2219hr/mL, respectively. Tenofovir exposure\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\nGeriatric Patients\\nPharmacokinetics of EFV, FTC, and tenofovir have not...","impact of renal impairment on EFV elimination should be minimal.\\nEmtricitabine and Tenofovir DF:\\n \\nThe pharmacokinetics of FTC and TDF are altered in\\nsubjects with renal impairment. In subjects with creatinine clearance below 50 mL/min,\\nC\\n and AUC\\n of FTC and tenofovir were increased \\n[see \\nWarnings and Precautions\\n(5.7)\\n].\\nPatients with Hepatic Impairment\\nEfavirenz:\\n \\nA multiple-dose trial showed no significant effect on EFV pharmacokinetics in\\nsubjects with mild hepatic impairment (Child-Pugh ...","hepatic impairment; however, FTC is not significantly metabolized by liver enzymes, so\\nthe impact of liver impairment should be limited.\\nTenofovir DF:\\n \\nThe pharmacokinetics of tenofovir following a 300 mg dose of TDF have\\nbeen studied in non-HIV infected subjects with moderate to severe hepatic impairment.\\nThere were no substantial alterations in tenofovir pharmacokinetics in subjects with\\nhepatic impairment compared with unimpaired subjects.\\nAssessment of Drug Interactions\\nThe drug interaction...","drug interaction trials have not been performed with EFV and NRTIs other than\\ntenofovir, lamivudine, and zidovudine. Clinically significant interactions would not be\\nexpected based on NRTIs elimination pathways.\\nEfavirenz has been shown \\nin vivo\\n to cause hepatic enzyme induction, thus increasing\\nthe biotransformation of some drugs metabolized by CYP3A and CYP2B6. \\nIn vitro\\nstudies have shown that EFV inhibited CYP isozymes 2C9 and 2C19 with K\\n values (8.5\\u2013\\n17 \\u00b5M) in the range of observed EFV pl...","concentrations well above those achieved clinically. Coadministration of EFV with drugs\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\nlowered plasma concentrations.\\nDrug interaction trials were performed with EFV and other drugs likely to be\\ncoadministered or drugs commonly used as probes for phar...",", AUC, and C\\n are\\nsummarized in Table 4 (effect of other drugs on EFV) and Table 5 (effect of EFV on\\nother drugs) \\n[see \\nDrug Interactions (7)\\n].\\nTable 4 Drug Interactions: Changes in Pharmacokinetic Parameters for EFV in\\nthe Presence of the Coadministered Drug\\nMean % Change of EFV\\nPharmacokinetic\\nParameters\\n (90% CI)\\nCoadministered Drug\\nDose of\\nCoadministered\\nDrug (mg)\\nEFV\\nDose\\n(mg)\\nN\\nC\\nAUC\\nC\\nLopinavir/ ritonavir\\n400/100 mg\\nq12h \\u00d7 9 days\\n600 mg\\nqd \\u00d7 9\\ndays\\n11,\\n12\\n\\u2194\\n\\u2193 16\\n(\\u2193 38 to\\n\\u2191 15)\\n\\u2193 16\\n(\\u2193 4...","20)\\n\\u2191 20\\n(\\u2191 15 to\\n\\u2191 26)\\nNA\\nRifabutin\\n300 mg qd \\u00d7 14\\ndays\\n600 mg\\nqd \\u00d7 14\\ndays\\n11\\n\\u2194\\n\\u2194\\n\\u2193 12\\n(\\u2193 24 to\\n\\u2191 1)\\nRifampin\\n600 mg \\u00d7 7 days\\n600 mg\\nqd \\u00d7 7\\ndays\\n12\\n\\u2193 20\\n(\\u2193 11 to\\n\\u2193 28)\\n\\u2193 26\\n(\\u2193 15 to\\n\\u2193 36)\\n\\u2193 32\\n(\\u2193 15 to\\n\\u2193 46)\\nArtemether/lumefantrine\\nArtemether 20\\nmg/lumefantrine\\n120 mg tablets (6\\n4-tablet doses\\nover 3 days)\\n600 mg\\nqd \\u00d7 26\\ndays\\n12\\n\\u2194\\n\\u219317\\nNA\\nSimvastatin\\n40 mg qd \\u00d7 4\\ndays\\n600 mg\\nqd \\u00d7 15\\ndays\\n14\\n\\u2193 12\\n(\\u2193 28 to\\n\\u2191 8)\\n\\u2194\\n\\u2193 12\\n(\\u2193 25 to\\n\\u2191 3)\\ni\\nmax\\nmin\\n*\\nmax\\nmin\\n\\u2020\\n\\u2021\\n\\u2021\\n\\u2021","NA = not available\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\nCarbamazepine\\n200 mg qd \\u00d7 3\\ndays, 200 mg bid\\n\\u00d7 3 days, then\\n400 mg qd \\u00d7 15\\ndays\\n600 mg\\nqd \\u00d7 35\\ndays\\n14\\n\\u2193 21\\n(\\u2193 15 to\\n\\u2193 26)\\n\\u2193 36\\n(\\u2193 32 to\\n\\u2193 40)\\n\\u2193 47\\n(\\u2193 41 to\\n\\u2193 53)\\nDiltiazem\\n240 mg \\u00d7 14\\ndays\\n600 mg\\nqd \\u00d7 28\\ndays\\n12\\n\\u2191 16\\n(\\u2191 6 to \\u2191\\n26)\\n\\u2191 11\\n(\\u2191 5 to \\u2191\\n18)\\n\\u2191 13\\n(\\u2191 1 to \\u2191\\n26)\\nVoriconazole\\n400 mg po q12h\\n\\u00d7 1 day then 200\\nmg po q12h \\u00d7 8\\ndays\\n400 mg\\nqd \\u00d7 9\\ndays\\nNA\\n\\u2191 38\\n\\u2191 44\\nNA\\n300 mg po q12h\\ndays 2\\u20137\\n300 mg\\nqd \\u00d7 7\\ndays\\nNA\\n\\u2193 14\\n \\n(\\u2193 7 to \\u2193\\n21)\\n\\u2194\\nNA\\n400 mg po q12h\\ndays 2\\u20137\\n300 m...","Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for\\nCoadministered Drug in the Presence of EFV\\nMean % Change of\\nCoadministered Drug\\nPharmacokinetic\\nParameters\\n (90% CI)\\nCoadministered Drug\\nDose of\\nCoadministered\\nDrug (mg)\\nEFV Dose\\n(mg)\\nN\\nC\\nAUC\\nC\\nAtazanavir\\n400 mg qd with a\\nlight meal d 1\\u201320\\n600 mg qd\\nwith a light\\nmeal d 7\\u2013\\n20\\n27\\n\\u2193 59\\n(\\u2193 49 to\\n\\u2193 67)\\n\\u2193 74\\n(\\u2193 68 to\\n\\u2193 78)\\n\\u2193 93\\n(\\u2193 90 to\\n\\u2193 95)\\n400 mg qd d 1\\u20136,\\nthen 300 mg qd\\nd 7\\u201320 with\\nritonavir 100 mg\\nqd and a light\\nmeal\\n600 mg qd\\n2...","meal\\n7\\u201320\\n300 mg\\nqd/ritonavir 100\\nmg qd d 1\\u201310\\n(pm), then 400\\nmg qd/ritonavir\\n100 mg qd d 11\\u2013\\n24 (pm)\\n(simultaneous\\nwith EFV)\\n600 mg qd\\nwith a light\\nsnack d\\n11\\u201324 (pm)\\n14\\n\\u2191 17\\n(\\u2191 8 to \\u2191\\n27)\\n\\u2194\\n\\u2193 42\\n(\\u2193 31 to\\n\\u2193 51)\\nIndinavir\\n1000 mg q8h \\u00d7\\n10 days\\n600 mg qd\\n\\u00d7 10 days\\n20\\nAfter morning dose\\n\\u2194\\n\\u2193 33\\n \\n(\\u2193 26 to\\n\\u2193 39)\\n\\u2193 39\\n \\n(\\u2193 24 to\\n\\u2193 51)\\nAfter afternoon dose\\n\\u2194\\n\\u2193 37\\n \\n(\\u2193 26 to\\n\\u2193 46)\\n\\u2193 52\\n \\n(\\u2193 47 to\\n\\u2193 57)\\nAfter evening dose\\n\\u2193 29\\n \\n(\\u2193 11 to\\n\\u2193 43)\\n\\u2193 46\\n \\n(\\u2193 37 to\\n\\u2193 54)\\n\\u2193 57\\n \\n(\\u2193 50 to\\n\\u2193 63)\\nLopinavir/ritona...","600 mg qd\\n\\u00d7 10 days\\n11\\nAfter AM dose\\n\\u2191 24\\n(\\u2191 12 to\\n\\u2191 38)\\n\\u2191 18\\n(\\u2191 6 to \\u2191\\n33)\\n\\u2191 42\\n(\\u2191 9 to \\u2191\\n86)\\nAfter PM dose\\n\\u2194\\n\\u2194\\n\\u2191 24\\n(\\u2191 3 to \\u2191\\n50)\\nSaquinavir SGC\\n1200 mg q8h \\u00d7\\n10 days\\n600 mg qd\\n\\u00d7 10 days\\n12\\n\\u2193 50\\n(\\u2193 28 to\\n\\u2193 66)\\n\\u2193 62\\n(\\u2193 45 to\\n\\u2193 74)\\n\\u2193 56\\n(\\u2193 16 to\\n\\u2193 77)\\nMaraviroc\\n100 mg bid\\n600 mg qd\\n12\\n\\u2193 51\\n(\\u2193 37 to\\n\\u2193 62)\\n\\u2193 45\\n(\\u2193 38 to\\n\\u2193 51)\\n\\u2193 45\\n(\\u2193 28 to\\n\\u2193 57)\\nRaltegravir\\n400 mg single\\ndose\\n600 mg qd\\n9\\n\\u2193 36\\n(\\u2193 2 to \\u2193\\n59)\\n\\u2193 36\\n(\\u2193 20 to\\n\\u2193 48)\\n\\u2193 21\\n(\\u2193 51 to\\n\\u2191 28)\\nBoceprevir\\n800 mg tid \\u00d7 6\\ndays\\n600 mg qd\\n\\u00d7 16 days\\nN...","days\\n\\u00d7 16 days\\nto \\u2191 8)\\n25)\\n58)\\nSimeprevir\\n150 mg qd \\u00d7 14\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n23\\n\\u2193 51\\n(\\u2193 46 to\\n\\u2193 56)\\n\\u2193 71\\n(\\u2193 67 to\\n\\u2193 74)\\n\\u2193 91\\n(\\u2193 88 to\\n\\u2193 92)\\nLedipasvir/sofosbuvir\\n90/400 mg qd \\u00d7\\n14 days\\n600 mg qd\\n\\u00d7 14 days\\nLedipasvir\\n15\\n\\u2193 34\\n(\\u2193 25 to\\n\\u2193 41)\\n\\u2193 34\\n(\\u2193 25 to\\n\\u2193 41)\\n\\u2193 34\\n(\\u2193 24 to\\n\\u2193 43)\\nSofosbuvir\\n\\u2194\\n\\u2194\\nNA\\nGS-331007\\n\\u2194\\n\\u2194\\n\\u2194\\nSofosbuvir\\n400 mg qd single\\ndose\\n600 mg qd\\n\\u00d714 days\\n16\\n\\u2193 19\\n(\\u2193 40 to\\n\\u2191 10)\\n\\u2194\\nNA\\nGS-331007\\n\\u2193 23\\n(\\u2193 16 to\\n\\u2193 30)\\n\\u2193 16\\n(\\u2193 24 to\\n\\u2193 8)\\nNA\\nSofosbuvir/velpatasvir\\n400/100 mg qd \\u00d7\\n14 days\\n600...","(\\u2191 32 to\\n\\u2191 69)\\n\\u2191 34\\n(\\u2191 18 to\\n\\u2191 53)\\n\\u2191 26\\n(\\u2191 9 to \\u2191\\n45)\\nItraconazole\\n200 mg q12h \\u00d7\\n28 days\\n600 mg qd\\n\\u00d7 14 days\\n18\\n\\u2193 37\\n(\\u2193 20 to\\n\\u2193 51)\\n\\u2193 39\\n(\\u2193 21 to\\n\\u2193 53)\\n\\u2193 44\\n(\\u2193 27 to\\n\\u2193 58)\\nHydroxy-itraconazole\\n\\u2193 35\\n(\\u2193 12 to\\n\\u2193 52)\\n\\u2193 37\\n(\\u2193 14 to\\n\\u2193 55)\\n\\u2193 43\\n(\\u2193 18 to\\n\\u2193 60)\\nPosaconazole\\n400 mg (oral\\nsuspension) bid\\n\\u00d7 10 and 20\\ndays\\n400 mg qd\\n\\u00d7 10 and\\n20 days\\n11\\n\\u2193 45\\n(\\u2193 34 to\\n\\u2193 53)\\n\\u2193 50\\n(\\u2193 40 to\\n\\u2193 57)\\nNA\\nRifabutin\\n300 mg qd \\u00d7 14\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n9\\n\\u2193 32\\n(\\u2193 15 to\\n\\u2193 46)\\n\\u2193 38\\n(\\u2193 28 to\\n\\u2193 47)\\n\\u2193 45\\n(\\u2193 31 to\\n\\u2193 56)\\nArt...","120 mg tablets (6\\n4-tablet doses\\nover 3 days)\\nArtemether\\n\\u2193 21\\u2193 38\\n\\u2193 51\\nNA\\ndihydroartemisinin\\n\\u2194\\n\\u2193 46\\nNA\\nlumefantrine\\n\\u219321\\nNA\\nAtorvastatin\\n10 mg qd \\u00d7 4\\ndays\\n600 mg qd\\n\\u00d7 15 days\\n14\\n\\u2193 14\\n(\\u2193 1 to \\u2193\\n26)\\n\\u2193 43\\n(\\u2193 34 to\\n\\u2193 50)\\n\\u2193 69\\n(\\u2193 49 to\\n\\u2193 81)\\nTotal active (including\\nmetabolites)\\n\\u2193 15\\n(\\u2193 2 to \\u2193\\n26)\\n\\u2193 32\\n(\\u2193 21 to\\n\\u2193 41)\\n\\u2193 48\\n(\\u2193 23 to\\n\\u2193 64)\\nPravastatin\\n40 mg qd \\u00d7 4\\ndays\\n600 mg qd\\n\\u00d7 15 days\\n13\\n\\u2193 32\\n(\\u2193 59 to\\n\\u2191 12)\\n\\u2193 44\\n(\\u2193 26 to\\n\\u2193 57)\\n\\u2193 19\\n(\\u2193 0 to \\u2193\\n35)\\nSimvastatin\\n40 mg qd \\u00d7 4\\ndays\\n600 mg qd\\n\\u00d7 15 days\\n14\\n\\u2193 7...","Epoxide metabolite\\n\\u2194\\n\\u2194\\n\\u2193 13\\n(\\u2193 30 to\\n\\u2191 7)\\nDiltiazem\\n240 mg \\u00d7 21\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n13\\n\\u2193 60\\n(\\u2193 50 to\\n\\u2193 68)\\n\\u2193 69\\n(\\u2193 55 to\\n\\u2193 79)\\n\\u2193 63\\n(\\u2193 44 to\\n\\u2193 75)\\nDesacetyl diltiazem\\n\\u2193 64\\n(\\u2193 57 to\\n\\u2193 69)\\n\\u2193 75\\n(\\u2193 59 to\\n\\u2193 84)\\n\\u2193 62\\n(\\u2193 44 to\\n\\u2193 75)\\nN-monodesmethyl\\ndiltiazem\\n\\u2193 28\\n(\\u2193 7 to \\u2193\\n44)\\n\\u2193 37\\n(\\u2193 17 to\\n\\u2193 52)\\n\\u2193 37\\n(\\u2193 17 to\\n\\u2193 52)\\nEthinyl\\nestradiol/norgestimate\\n0.035 mg/0.25\\nmg \\u00d7 14 days\\n600 mg qd\\n\\u00d7 14 days\\nEthinyl estradiol\\n21\\n\\u2194\\n\\u2194\\n\\u2194\\nNorelgestromin\\n21\\n\\u2193 46\\n(\\u219339 to\\n\\u2193 52)\\n\\u2193 64\\n(\\u2193 62 to\\n\\u2193 67)\\n\\u2193 82\\n(\\u2193 79 to\\n\\u2193 85)\\nL...","NA = not available\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\n#\\n\\u00de\\n\\u00df\\n\\u00e0\\n\\u00e8\\n\\u00f0\\n\\u00f8\\n\\u00fd\\n\\u00a3\\nMethadone\\nmaintenance 35\\u2013\\n100 mg daily\\n\\u00d7 14\\u201321\\ndays\\n11\\n(\\u2193 25 to\\n\\u2193 59)\\n(\\u2193 33 to\\n\\u2193 66)\\nNA\\nBupropion\\n150 mg single\\ndose (sustained-\\nrelease)\\n600 mg qd\\n\\u00d7 14 days\\n13\\n\\u2193 34\\n(\\u219321 to\\n\\u219347)\\n\\u2193 55\\n(\\u219348 to\\n\\u219362)\\nNA\\nHydroxybupropion\\n\\u2191 50\\n(\\u2191 20 to\\n\\u2191 80)\\n\\u2194\\nNA\\nSertraline\\n50 mg qd \\u00d7 14\\ndays\\n600 mg qd\\n\\u00d7 14 days\\n13\\n\\u2193 29\\n(\\u2193 15 to\\n\\u2193 40)\\n\\u2193 39\\n(\\u2193 27 to\\n\\u2193 50)\\n\\u2193 46\\n(\\u2193 31 to\\n\\u2193 58)\\nVoriconazole\\n400 mg po q12h\\n\\u00d7 1 day then 200\\nmg po q12h \\u00d7 8\\ndays\\n400 mg qd\\n\\u00d7 9 days\\nNA\\n\\u2193 61\\n\\u2193 77\\nN...","were unaffected when FTC and TDF were administered together versus each agent\\ndosed alone.\\nIn vitro\\n and clinical pharmacokinetic drug-drug interaction studies have shown that the\\npotential for CYP mediated interactions involving FTC and tenofovir with other medicinal\\nproducts is low.\\nTDF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)\\ntransporters. When TDF is coadministered with an inhibitor of these transporters, an\\nincrease in absorption may be observed.\\nN...","Parallel-group design; N for EFV + lopinavir/ritonavir, N for lopinavir/ritonavir alone.\\nValues are for lopinavir. The pharmacokinetics of ritonavir 100 mg q12h are unaffected by\\nconcurrent EFV.\\n95% CI\\nSoft Gelatin Capsule\\nStudy conducted with ATRIPLA coadministered with HARVONI.\\nThe predominant circulating nucleoside metabolite of sofosbuvir.\\nStudy conducted with ATRIPLA coadministered with SOVALDI\\u2122 (sofosbuvir).\\nStudy conducted with ATRIPLA coadministered with EPCLUSA.\\nNot available because of...","no clinically significant drug interactions have been observed between TDF and abacavir,\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\nconducted in healthy volunteers.\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\ntenofovir pharmacokinetics we...","of\\ncoadministered drugs are shown in Table 7.\\nTable 6 Drug Interactions: Changes in Pharmacokinetic Parameters for\\nTenofovir in the Presence of the Coadministered Drug\\nCoadministered\\nDrug\\nDose of\\nCoadministered\\nDrug (mg)\\nN\\nMean % Change of Tenofovir\\nPharmacokinetic Parameters\\n \\n(90% CI)\\nC\\nAUC\\nC\\n*\\nAtazanavir\\n400 once daily \\u00d7\\n14 days\\n33\\n\\u2191 14\\n(\\u2191 8 to \\u2191 20)\\n\\u2191 24\\n(\\u2191 21 to \\u2191\\n28)\\n\\u2191 22\\n(\\u2191 15 to \\u2191\\n30)\\nAtazanavir/ritonavir\\n300/100 once\\ndaily\\n12\\n\\u2191 34\\n(\\u2191 20 to \\u2191\\n51)\\n\\u2191 37\\n(\\u2191 30 to \\u2191\\n45)\\n\\u2191 29\\n(\\u2191 21 to \\u2191\\n36)\\nD...","24\\n\\u2194\\n\\u2191 32\\n(\\u2191 25 to \\u2191\\n38)\\n\\u2191 51\\n(\\u2191 37 to \\u2191\\n66)\\nSofosbuvir\\n400 once daily\\n16\\n\\u2191 25\\n(\\u2191 8 to \\u2191 45)\\n\\u2194\\n\\u2194\\nSofosbuvir/velpatasvir\\n400/100 once\\ndaily\\n15\\n\\u2191 77\\n(\\u2191 53 to \\u2191\\n104)\\n\\u2191 81\\n(\\u2191 68 to \\u2191\\n94)\\n\\u2191 121\\n(\\u2191 100 to \\u2191\\n143)\\nTipranavir/ritonavir\\n500/100 twice\\ndaily\\n22\\n\\u2193 23\\n(\\u2193 32 to \\u2193\\n13)\\n\\u2193 2\\n(\\u2193 9 to \\u2191 5)\\n\\u2191 7\\n(\\u2193 2 to \\u2191 17)\\n750/200 twice\\ndaily (23 doses)\\n20\\n\\u2193 38\\n(\\u2193 46 to \\u2193\\n29)\\n\\u2191 2\\n(\\u2193 6 to \\u2191 10)\\n\\u2191 14\\n(\\u2191 1 to \\u2191 27)\\nmax\\nmin\\nmax\\nmin\\n*\\n,\\n\\u2020\\n\\u2021\\nmax\\nmin\\nAll interaction trials conducted in healthy volunteers.\\nSubjects receive...","*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\n#\\n\\u00de\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\nCoadministered Drug in the Presence of TDF\\nCoadministered\\nDrug\\nDose of\\nCoadministered\\nDrug (mg)\\nN\\nMean % Change of Coadministered\\nDrug Pharmacokinetic Parameters\\n \\n(90% CI)\\nC\\nAUC\\nC\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\n\\u00b6\\n#\\n\\u00de\\n\\u00df\\n\\u00e0\\n\\u00e8\\nAtazanavir\\n400 once daily \\u00d7\\n14 days\\n34\\n\\u2193 21\\n(\\u2193 27 to \\u2193 14)\\n\\u2193 25\\n(\\u2193 30 to \\u2193 19)\\n\\u2193 40\\n(\\u2193 48 to \\u2193 32)\\nAtazanavir/ritonavir\\n300/100 once daily\\n\\u00d7 42 days\\n10\\n\\u2193 28\\n(\\u2193 50 to \\u2191 5)\\n\\u2193 25\\n \\n(\\u2193 42 to \\u2193 3)\\n\\u2193 23\\n \\n(\\u2193 46 to \\u2191 10)\\nDa...","400/100 twice daily\\n\\u00d7 14 days\\n24\\n\\u2194\\n\\u2194\\n\\u2194\\nTipranavir\\nTipranavir/ritonavir\\n500/100 twice daily\\n22\\n\\u2193 17\\n(\\u2193 26 to \\u2193 6)\\n\\u2193 18\\n(\\u2193 25 to \\u2193 9)\\n\\u2193 21\\n(\\u2193 30 to \\u2193 10)\\nTipranavir/ritonavir\\n750/200 twice daily\\n(23 doses)\\n20\\n\\u2193 11\\n(\\u2193 16 to \\u2193 4)\\n\\u2193 9\\n(\\u2193 15 to \\u2193 3)\\n\\u2193 12\\n(\\u2193 22 to 0)\\n12.4 Microbiology\\nMechanism of Action\\nSubjects received TDF 300 mg once daily.\\nIncrease = \\u2191; Decrease = \\u2193; No Effect = \\u2194\\nReyataz Prescribing Information.\\nPrezista Prescribing Information.\\nSubjects received didanosine buffered tablets.\\nApti...","AUC and C\\n values of atazanavir that were 2.3- and 4-fold higher than the respective values\\nobserved for atazanavir 400 mg when given alone.\\nmin\\nPrezista Prescribing Information.\\nVidex EC Prescribing Information. \\nSubjects received didanosine enteric-coated capsules.\\n373 kcal, 8.2 g fat.\\nCompared with didanosine (enteric-coated) 400 mg administered alone under fasting conditions.\\nAptivus Prescribing Information.\\n\\u00a7\\n\\u00b6\\n\\u00b6\\n#\\n\\u00de\\n\\u00df\\n\\u00e0\\n\\u00e0\\n\\u00e8","Efavirenz:\\n \\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\u03b1, \\u03b2, \\u03b3, and \\u03b4 are\\nnot inhibited by EFV.\\nEmtricitabine:\\n \\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\nthe activity of the HIV-1 RT by competing wi...","Tenofovir DF:\\n \\nTDF is an acyclic nucleoside phosphonate diester analog of adenosine\\nmonophosphate. TDF requires initial diester hydrolysis for conversion to tenofovir and\\nsubsequent phosphorylations by cellular enzymes to form tenofovir diphosphate.\\nTenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural\\nsubstrate deoxyadenosine 5\\u2032-triphosphate and, after incorporation into DNA, by DNA\\nchain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA\\npo...","Efavirenz:\\n \\nThe concentration of EFV inhibiting replication of wild-type laboratory adapted\\nstrains and clinical isolates in cell culture by 90\\u201395% (EC\\n) ranged from 1.7\\u201325 nM in\\nlymphoblastoid cell lines, peripheral blood mononuclear cells, and macrophage/monocyte\\ncultures. Efavirenz demonstrated additive antiviral activity against HIV-1 in cell culture\\nwhen combined with non-nucleoside reverse transcriptase inhibitors (NNRTIs)\\n(delavirdine and nevirapine), nucleoside reverse transcriptase inh...","activity in cell culture with atazanavir. Efavirenz demonstrated antiviral activity against\\nclade B and most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, and N), but had\\nreduced antiviral activity against group O viruses. Efavirenz is not active against HIV-2.\\nEmtricitabine:\\n \\nThe antiviral activity in cell culture of FTC against laboratory and clinical\\nisolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and\\nperipheral blood mononuclear cells. The 50...","saquinavir), additive to synergistic effects were observed. Emtricitabine displayed\\nantiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC\\n values\\nranged from 0.007\\u20130.075 \\u00b5M) and showed strain specific activity against HIV-2 (EC\\nvalues ranged from 0.007\\u20131.5 \\u00b5M).\\nTenofovir DF:\\n \\nThe antiviral activity in cell culture of tenofovir against laboratory and\\nclinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary\\nmonocyte/macrophage cells and periphera...","tenofovir were in the range of 0.04\\u20138.5 \\u00b5M. In drug combination studies of tenofovir\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\n(EC\\n values ranged from 0.5\\u20132.2 \\u00b5M) and showed strain-specific ...","In addition, a K70E substitution in HIV-1 reverse transcriptase has been selected by\\ntenofovir and results in reduced susceptibility to tenofovir.\\nIn a clinical trial of treatment-na\\u00efve subjects \\n[Study 934,\\n see \\nClinical Studies (14)\\n]\\nresistance analysis was performed on HIV-1 isolates from all confirmed virologic failure\\nsubjects with greater than 400 copies/mL of HIV-1 RNA at Week 144 or early\\ndiscontinuations. Genotypic resistance to EFV, predominantly the K103N substitution,\\nwas the most ...","analyzed subject isolates in the FTC + TDF group and in 10/29 analyzed subject isolates\\nin the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects\\ndeveloped a detectable K65R substitution in their HIV-1 as analyzed through standard\\ngenotypic analysis.\\nIn a clinical trial of treatment-na\\u00efve subjects, isolates from 8/47 (17%) analyzed subjects\\nreceiving TDF developed the K65R substitution through 144 weeks of therapy; 7 of\\nthese occurred in the first 48 weeks of treatment and ...","resulting in the K65R amino acid substitution.\\nEfavirenz:\\n \\nClinical isolates with reduced susceptibility in cell culture to EFV have been\\nobtained. The most frequently observed amino acid substitution in clinical trials with EFV\\nis K103N (54%). One or more RT substitutions at amino acid positions 98, 100, 101,\\n103, 106, 108, 188, 190, 225, 227, and 230 were observed in subjects failing treatment\\nwith EFV in combination with other antiretrovirals. Other resistance substitutions\\nobserved to emerg...","V179D, double substitutions L100I/V108I, and triple substitutions L100I/V179D/Y181C in\\nRT.\\nEmtricitabine:\\n \\nEmtricitabine-resistant isolates of HIV-1 have been selected in cell culture\\nand in clinical trials. Genotypic analysis of these isolates showed that the reduced\\n50\\n50\\n50\\n90","susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\n(M184V/I).\\nTenofovir DF:\\n \\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\nfold reduction in susceptibility to tenofovir.\\nCross Resistance\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\n Cross resistance has been ...","Therefore, cross resistance among these drugs may occur in patients whose virus\\nharbors either or both of these amino acid substitutions.\\nEfavirenz:\\n \\nClinical isolates previously characterized as EFV resistant were also\\nphenotypically resistant in cell culture to delavirdine and nevirapine compared to\\nbaseline. Delavirdine- and/or nevirapine-resistant clinical viral isolates with NNRTI\\nresistance-associated substitutions (A98G, L100I, K101E/P, K103N/S, V106A, Y181X,\\nY188X, G190X, P225H, F227L, ...","zidovudine, and NNRTIs (delavirdine, EFV, and nevirapine). HIV-1 isolates containing the\\nK65R substitution, selected \\nin vivo\\n by abacavir, didanosine, and tenofovir, demonstrated\\nreduced susceptibility to inhibition by FTC. Viruses harboring substitutions conferring\\nreduced susceptibility to stavudine and zidovudine (M41L, D67N, K70R, L210W,\\nT215Y/F, and K219Q/E) or didanosine (L74V) remained sensitive to FTC.\\nTenofovir DF:\\n \\nCross resistance has been observed among NRTIs. The K65R substitution...","drugs may occur in patients whose virus harbors the K65R substitution. The K70E\\nsubstitution selected clinically by TDF results in reduced susceptibility to abacavir,\\ndidanosine, FTC, and lamivudine. HIV-1 isolates from subjects (N=20) whose HIV-1\\nexpressed a mean of 3 zidovudine-associated RT amino acid substitutions (M41L, D67N,\\nK70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility\\nto tenofovir. Subjects whose virus expressed an L74V substitution without zidovudi...","Efavirenz:\\n \\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\nwere increased above background in females. No increases in tumor incidence above\\nbackground were seen in males. In studies in which rats were administered EFV at\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\n...","or clastogenic activity in a battery of \\nin vitro\\n and \\nin vivo\\n studies. These included bacterial\\nmutation assays in \\nS. typhimurium\\n and \\nE. coli\\n, mammalian mutation assays in Chinese\\nhamster ovary cells, chromosome aberration assays in human peripheral blood\\nlymphocytes or Chinese hamster ovary cells, and an \\nin vivo\\n mouse bone marrow\\nmicronucleus assay. Given the lack of genotoxic activity of EFV, the relevance to\\nhumans of neoplasms in EFV-treated mice is not known.\\nEfavirenz did not impa...","humans given therapeutic doses of EFV.\\nEmtricitabine:\\n \\nIn long-term carcinogenicity studies of FTC, no drug-related increases in\\ntumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human\\nsystemic exposure at the therapeutic dose of 200 mg/day) or in rats at doses up to 600\\nmg/day (31 times the human systemic exposure at the therapeutic dose).\\nEmtricitabine was not genotoxic in the reverse mutation bacterial test (Ames test), or\\nthe mouse lymphoma or mouse micronucleus ...","daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of\\napproximately 60-fold higher than human exposures at the recommended 200 mg daily\\ndose.\\nTenofovir DF:\\n \\nLong-term oral carcinogenicity studies of TDF in mice and rats were\\ncarried out at exposures up to approximately 16 times (mice) and 5 times (rats) those\\nobserved in humans at the therapeutic dose for HIV-1 infection. At the high dose in\\nfemale mice, liver adenomas were increased at exposures 16 times that i...","was negative when administered to male mice.\\nThere were no effects on fertility, mating performance, or early embryonic development\\nwhen TDF was administered to male rats at a dose equivalent to 10 times the human\\ndose based on body surface area comparisons for 28 days prior to mating and to\\nfemale rats for 15 days prior to mating through Day 7 of gestation. There was, however,","an alteration of the estrous cycle in female rats.\\n13.2 Animal Toxicology and/or Pharmacology\\nEfavirenz:\\n \\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\nrecommended dose.\\nTenofovir DF:\\n \\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\nin humans caused bone toxicity. In monkeys...","unknown.\\nEvidence of renal toxicity was noted in 4 animal species administered tenofovir and TDF.\\nIncreases in serum creatinine, BUN, glycosuria, proteinuria, phosphaturia and/or\\ncalciuria and decreases in serum phosphate were observed to varying degrees in these\\nanimals. These toxicities were noted at exposures (based on AUCs) 2- to 20-times\\nhigher than those observed in humans. The relationship of the renal abnormalities,\\nparticularly the phosphaturia, to the bone toxicity is not known.\\n14 CLI...","virologic failure who switched from their current regimen to ATRIPLA.\\nIn antiretroviral treatment-experienced patients, the use of ATRIPLA tablets may be\\nconsidered for patients with HIV-1 strains that are expected to be susceptible to the\\ncomponents of ATRIPLA as assessed by treatment history or by genotypic or\\nphenotypic testing \\n[see \\nMicrobiology (12.4)\\n].\\nStudy 934:\\n \\nData through 144 weeks are reported for Study 934, a randomized, open-\\nlabel, active-controlled multicenter trial comparing ...","TDF with EFV. Subjects had a mean age of 38 years (range 18\\u201380); 86% were male, 59%\\nwere Caucasian, and 23% were Black. The mean baseline CD4\\n cell count was 245\\ncells/mm\\n (range 2\\u20131191), and median baseline plasma HIV-1 RNA was 5.01 log\\ncopies/mL (range 3.56\\u20136.54). Subjects were stratified by baseline CD4\\n cell count (&lt; or\\n\\u2265200 cells/mm\\n), and 41% had CD4\\n cell counts &lt;200 cells/mm\\n. Fifty-one percent\\n(51%) of subjects had baseline viral loads &gt;100,000 copies/mL. Treatment outcomes\\nthrough 48 a...","Outcomes\\nAt Week 48\\nAt Week 144\\nFTC+TDF+EFV\\n(N=244)\\nAZT/3TC+EFV\\n(N=243)\\nFTC+TDF+\\nEFV\\n(N=227)\\nAZT/3TC+EFV\\n(N=229)\\n*\\n\\u2020\\n\\u2021\\n\\u00a7\\nResponder\\n84%\\n73%\\n71%\\n58%\\nVirologic failure\\n2%\\n4%\\n3%\\n6%\\n  Rebound\\n1%\\n3%\\n2%\\n5%\\n  Never suppressed\\n0%\\n0%\\n0%\\n0%\\n  Change in antiretroviral\\nregimen\\n1%\\n1%\\n1%\\n1%\\nDeath\\n&lt;1%\\n1%\\n1%\\n1%\\nDiscontinued due to\\nadverse event\\n4%\\n9%\\n5%\\n12%\\nDiscontinued for other\\nreasons\\n10%\\n14%\\n20%\\n22%\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\nzidovudine/lamivudine group, respectiv...","other reasons in the zidovudine/lamivudine group in this open-label trial. In addition, 80%\\nand 70% of subjects in the FTC + TDF group and the zidovudine/lamivudine group,\\nrespectively, achieved and maintained HIV-1 RNA &lt;50 copies/mL through Week 48 (64%\\nand 56% through Week 144). The mean increase from baseline in CD4\\n cell count was\\n190 cells/mm\\n in the FTC + TDF group and 158 cells/mm\\n in the zidovudine/lamivudine\\ngroup at Week 48 (312 and 271 cells/mm\\n at Week 144).\\nThrough 48 weeks, 7 subje...","stable virologic suppression on combination antiretroviral therapy consisting of at least\\ntwo NRTIs administered in combination with a protease inhibitor (with or without\\nritonavir) or a NNRTI.\\nTo be enrolled, subjects were to have HIV-1 RNA &lt;200 copies/mL for at least 12 weeks\\non their current regimen prior to trial entry with no known HIV-1 substitutions\\nconferring resistance to the components of ATRIPLA and no history of virologic failure.\\nThe trial compared the efficacy of switching to ATRIP...","consent to continue trial after Week 48 or Week 96 were excluded from analysis.\\nSubjects achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Weeks 48 and\\n144.\\nIncludes confirmed viral rebound and failure to achieve confirmed HIV-1 RNA &lt;400 copies/mL\\nthrough Weeks 48 and 144.\\nIncludes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other\\nreasons.\\n\\u2020\\n\\u2021\\n\\u00a7\\n+\\n3\\n3\\n3","22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\nand 3% were of other races. At baseline, median CD4\\n cell count was 516 cells/mm\\n,\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\nregimen at trial enrollment.\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...","sides. Each bottle contains 30 tablets and silica gel desiccant, and is closed with a child-\\nresistant closure.\\nStore below 30 \\u00b0C (86 \\u00b0F).\\nKeep container tightly closed.\\nDispense only in original container.\\n17 PATIENT COUNSELING INFORMATION\\nAdvise the patient to read the approved patient labeling (Patient Information).\\nSevere Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV\\nInform patients that severe acute exacerbations of hepatitis B have been reported in\\npatients wh...","close medical follow-up for several months after stopping ATRIPLA to monitor for\\nexacerbations of hepatitis \\n[see \\nWarnings and Precautions (5.1)\\n].\\nRash\\nInform patients that a common side effect is rash, and that rashes usually go away\\nwithout any change in treatment. However, since rash may be serious, advise patients\\nto contact their physician promptly if rash occurs \\n[see \\nWarnings and Precautions (5.2)\\n].\\nHepatotoxicity\\nInform patients to watch for early warning signs of liver inflammation ...","[see \\nWarnings and Precautions\\n(5.3)\\n and \\nAdverse Reactions (6.1)\\n]\\n.\\nDrug Interactions\\nAdvise patients that ATRIPLA may interact with many drugs; therefore, advise patients\\nto report to their healthcare provider the use of any other medication, including other\\ndrugs for treatment of hepatitis C virus \\n[see \\nWarnings and Precautions (5.4)\\n and \\nDrug\\n+\\n3\\n+","Interactions (7)\\n]\\n.\\nPsychiatric Symptoms\\nInform patients that serious psychiatric symptoms including severe depression,\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\n[see \\nWarnings and Precautions (5.5)\\n]\\n.\\nAdvise patients to seek immediate medical evaluation if they experience severe\\npsychiatric adverse experiences.\\nAdvise patients to inform their physician of any history o...","Dosing at bedtime may improve the tolerability of these symptoms, which are likely to\\nimprove with continued therapy.\\nAlert patients to the potential for additive effects when ATRIPLA is used\\nconcomitantly with alcohol or psychoactive drugs.\\nInstruct patients that if they experience NSS to avoid potentially hazardous tasks\\nsuch as driving or operating machinery \\n[see \\nWarnings and Precautions (5.6)\\n and\\nDosage and Administration (2.2)\\n].\\nInform patients that there is a risk of developing late-on...","syndrome, has been reported. Advise patients to avoid using ATRIPLA with concurrent\\nor recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs) \\n[see \\nWarnings\\nand Precautions (5.7)\\n].\\nEmbryo-Fetal Toxicity\\nApprise patients of the potential harm to the fetus if ATRIPLA is used during the first\\ntrimester of pregnancy, or if the patient becomes pregnant while taking this drug.\\nInstruct adults and adolescents of childbearing potential receiving ATRIPLA to avoid\\npregnancy and to notify...","half-life of EFV, recommend use of adequate contraceptive measures for 12 weeks after\\ndiscontinuation of ATRIPLA \\n[see \\nUse in Specific Populations (8.1\\n, \\n8.3)\\n]\\n.\\nBone Loss and Mineralization Defects\\nInform patients that decreases in bone mineral density have been observed with the use\\nof TDF, a component of ATRIPLA. Advise patients that bone mineral density monitoring\\nmay be performed in patients who have a history of pathologic bone fracture or other\\nrisk factors for osteoporosis or bone los...","Convulsions\\nInform patients that convulsions have been reported with the use of EFV, a component\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\nmetabolized by the liver may require periodic monitoring of plasma levels \\n[see \\nWarnings\\nand Precautions (5.10)\\n and \\nDrug Interactions (7.3)\\n]\\n.\\nLactic Acidosis and Severe Hepatomegaly\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\nfatal cases, have been reported. Treatmen...","symptoms of inflammation from previous infections may occur soon after anti-HIV\\ntreatment is started. It is believed that these symptoms are due to an improvement in\\nthe body&#x27;s immune response, enabling the body to fight infections that may have been\\npresent with no obvious symptoms. Advise patients to inform their healthcare provider\\nimmediately of any symptoms of infection \\n[see \\nWarnings and Precautions (5.12)\\n]\\n.\\nFat Redistribution\\nInform patients that redistribution or accumulation of body ...","take ATRIPLA on a regular dosing schedule to avoid missing doses. Advise patients that\\ndosing at bedtime may improve the tolerability of nervous system symptoms \\n[see\\nDosage and Administration (2.1)\\n].\\nPregnancy Registry\\nAdvise patients that there is a pregnancy exposure registry that monitors pregnancy\\noutcomes in patients exposed to ATRIPLA during pregnancy \\n[see \\nUse in Specific\\nPopulations (8.1)\\n]\\n.\\nLactation\\nInstruct patients not to breastfeed because HIV-1 can be passed to the baby in the\\n...","Patient Information\\n \\nATRIPLA\\u2122 (uh TRIP luh)\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\nWhat is the most important information I should know about ATRIPLA?\\nATRIPLA can cause serious side effects, including:\\nWorsening of hepatitis B virus (HBV) infection.\\n Your healthcare provider will\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\nA\\n\\"flare-up\\" is when yo...","health often and do blood tests regularly for several months to check your HBV\\ninfection, or give you a medication to treat hepatitis B. Tell your healthcare\\nprovider about any new or unusual symptoms you may have after you stop\\ntaking ATRIPLA.\\nFor more information about side effects see the section, \\n\\"\\nWhat are the possible\\nside effects of ATRIPLA?\\n\\"\\nWhat is ATRIPLA?\\n \\nATRIPLA is a prescription medicine that contains efavirenz, emtricitabine, and tenofovir\\ndisoproxil fumarate combined in 1 tabl...","who weigh less than 88 lbs (40 kg).\\nWho should not take ATRIPLA?\\nDo not take ATRIPLA if you:\\nare allergic to efavirenz\\ntake the medicine called voriconazole, elbasvir or grazoprevir\\nAsk your healthcare provider if you are not sure if you take any of these medicines.\\nBefore taking ATRIPLA\\n, tell your healthcare provider about all of your medical\\nconditions, including if you:\\nhave liver problems, including hepatitis B or C virus infection\\nhave heart problems\\nhave or have had mental problems\\nhave a...","test before you start treatment with ATRIPLA. \\nYou should not become pregnant\\nduring treatment with ATRIPLA and for 12 weeks after stopping\\ntreatment.\\n Tell your healthcare provider if you become pregnant or think you may","be pregnant during treatment with ATRIPLA.\\nFemales who are able to become pregnant should use 2 effective\\nforms of birth control (contraception) during treatment with ATRIPLA\\nand for 12 weeks after stopping treatment.\\nA barrier form of birth control should always be used along with\\nanother type of birth control\\n. Barrier forms of birth control may include\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\nBirth control methods that contain the hormone progesterone such ...","ATRIPLA during pregnancy. The purpose of this registry is to collect information\\nabout the health of you and your baby. Talk to your healthcare provider about\\nhow you can take part in this registry.\\nare breastfeeding or plan to breastfeed. ATRIPLA can pass into your breast milk. Do\\nnot breastfeed because of the risk of passing HIV-1 to your baby.\\nTell your healthcare provider about all the medicines you take\\n, including\\nprescription and over-the-counter medicines, vitamins and herbal supplements...","healthcare provider can tell you if it is safe to take ATRIPLA with other medicines.\\nHow should I take ATRIPLA?\\nTake ATRIPLA exactly as your healthcare provider tells you to.\\nIf you take ATRIPLA with other medicines used to treat HIV-1, your healthcare\\nprovider will tell you what medicines to take and how to take them.\\nTake ATRIPLA 1 time each day on an empty stomach. You should take ATRIPLA at\\nthe same time each day.\\nTaking ATRIPLA at bedtime may make some side effects less bothersome.\\nDo not m...","with ATRIPLA.\\nIf you take too much ATRIPLA, call your healthcare provider or got to the nearest\\nhospital emergency room right away.\\nWhat should I avoid while taking ATRIPLA?\\nATRIPLA can cause dizziness, impaired concentration and drowsiness. If you have\\nthese symptoms, do not drive a car, use heavy machinery, or do anything that\\nrequires you to be alert.\\nWhat are the possible side effects of ATRIPLA?\\nATRIPLA may cause serious side effects, including:","See \\"\\nWhat is the most important information I should know about\\nATRIPLA?\\n\\"\\nRash.\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\naway without any change in your treatment. Tell your healthcare provider right away\\nif you develop a rash during treatment with ATRIPLA.\\nSevere liver problems. I\\nn rare cases, severe liver problems can happen that can\\nlead to death. \\nTell your healthcare provider right away if you get these\\nsymptoms:\\n skin or the white part of your eyes ...","manic reactions have happened in people who take ATRIPLA. These mental health\\nproblems may happen more often in people who have a history of mental problems\\nor drug use, or who take medicines to treat mental problems. Tell your healthcare\\nprovider right away if you develop serious mental problems during treatment with\\nATRIPLA.\\nNervous system problems.\\n Nervous system problems usually begin during the\\nfirst or second day of treatment with ATRIPLA and usually go away after 2 to 4\\nweeks of treatmen...","ATRIPLA. Symptoms of nervous system problems may include:\\ndizziness\\nproblems concentrating\\nabnormal dreams\\nunusually happy mood\\nagitation\\nthought problems\\nslow thoughts and physical\\nmovement\\nproblems sleeping\\nexcessive sleepiness or difficulty\\nawakening\\nseeing or hearing things that are not real\\n(hallucinations)\\nconfusion\\nmemory problems\\nlack of coordination or difficulty with\\nbalance\\nIf you have dizziness, trouble concentrating or sleepiness, do not drive a car, use\\nmachinery, or do anything th...","ATRIPLA if you develop new or worse kidney problems during treatment with\\nATRIPLA.\\nBone problems\\n can happen in some people who take ATRIPLA. Bone problems\\ninclude bone pain or softening or thinning of bones, which may lead to fractures.\\nYour healthcare provider may need to do tests to check your bones.\\nSeizures.\\n Your healthcare provider may do blood tests during treatment with\\nATRIPLA if you take certain medicines used to prevent seizures.\\nToo much lactic acid in your blood (lactic acidosis).\\n...","provider right away if you develop any of these symptoms:\\nweakness or being more tired than\\nusual\\nbeing short of breath or fast\\nbreathing\\ncold or blue hands and feet\\nfast or abnormal heartbeat\\nunusual muscle pain\\nstomach pain with nausea and vomiting\\nfeel dizzy or lightheaded\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\n Your\\nimmune system may get stronger and begin to fight infections that have been hidden...","fat in the upper back and neck (\\"buffalo hump\\"), in the breasts, and around the\\ntrunk. Loss of fat from the legs, arms, and face may also happen. The cause and\\nlong-term health effects of these body fat changes are not known.\\nThe most common side effects of ATRIPLA include:\\ndiarrhea\\ntiredness\\ndizziness\\nproblems sleeping\\nrash\\nnausea\\nheadache\\ndepression\\nabnormal dreams\\nThese are not all the possible side effects of ATRIPLA. \\nCall your doctor for medical advice about side effects. You may report si...","Medicines are sometimes prescribed for purposes other than those listed in a Patient\\nInformation leaflet. Do not use ATRIPLA for a condition for which it was not prescribed.\\nDo not give ATRIPLA to other people, even if they have the same symptoms that you\\nhave. It may harm them. You can ask your healthcare provider or pharmacist for\\ninformation about ATRIPLA that is written for health professionals.\\nWhat are the ingredients of ATRIPLA?\\nActive Ingredients:\\n efavirenz, emtricitabine, and tenofovir...","Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404\\nATRIPLA, EMTRIVA, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc., or\\nits related companies. All other trademarks referenced herein are the property of their","respective owners.\\n\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\n21937-GS-020A\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\n61958-1601-3\\n30 tablets\\nATRIPLA\\u2122\\n(efavirenz 600 mg/emtricitabine 200 mg/\\ntenofovir disoproxil fumarate 300 mg)\\ntablets\\nGILEAD ACCESS PROGRAM\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\nALERT: Find out about medicines that\\nshould NOT be taken with ATRIPLA\\nRx only\\nPOM\\nATRIPLA ACCESS  \\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...","Gilead Sciences, Inc.\\nIngredient Name\\nBasis of Strength\\nStrength\\nEFAVIRENZ\\n (UNII: JE6H2O27P8) \\n(EFAVIRENZ - UNII:JE6H2O27P8)\\nEFAVIRENZ\\n600 mg\\nEMTRICITABINE\\n (UNII: G70B4ETF4S) \\n(EMTRICITABINE - UNII:G70B4ETF4S)\\nEMTRICITABINE\\n200 mg\\nTENOFOVIR DISOPROXIL FUMARATE\\n (UNII: OTT9J7900I) \\n(TENOFOVIR\\nANHYDROUS - UNII:W4HFE001U5)\\nTENOFOVIR DISOPROXIL\\nFUMARATE\\n300 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\n (UNII: RF...","TITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nProduct Characteristics\\nColor\\nWHITE\\nScore\\nno score\\nShape\\nOVAL\\nSize\\n20mm\\nFlavor\\nImprint Code\\n123\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:61958-\\n1601-1\\n30 \\nin 1 BOTTLE, PLASTIC; Type 0: Not a\\nCombination Product\\n07/20/2006\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nEXPORT ONLY\\n07/20/2006\\nLabeler - \\nGilead Sciences, Inc. ..."]],["color",{"type":"ndarray","array":["#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#999","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#999","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#aec7e8","#aec7e8","#1f77b4","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#999","#1f77b4","#aec7e8","#1f77b4","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#999","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4"],"shape":[181],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1287","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1288"}}},"glyph":{"type":"object","name":"Scatter","id":"p1283","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1284","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1285","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1254","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p1269","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p1270"},{"type":"object","name":"WheelZoomTool","id":"p1271","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1272","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1273","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1278"},{"type":"object","name":"SaveTool","id":"p1279"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1264","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1265","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1266"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1267"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1259","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1260","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1261"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1262"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1263","attributes":{"axis":{"id":"p1259"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1268","attributes":{"dimension":1,"axis":{"id":"p1264"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1289","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1290","attributes":{"label":{"type":"value","value":"Antiretroviral Therapy"},"renderers":[{"id":"p1286"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1291","attributes":{"label":{"type":"value","value":"Antiretroviral Therapy Interactions"},"renderers":[{"id":"p1286"}],"index":105}},{"type":"object","name":"LegendItem","id":"p1292","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p1286"}],"index":42}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p1361","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p1298","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1307","attributes":{"start":-0.9166807293891908,"end":8.752451610565185}},"y_range":{"type":"object","name":"Range1d","id":"p1308","attributes":{"start":-2.575758934020996,"end":7.232198476791382}},"x_scale":{"type":"object","name":"LinearScale","id":"p1309"},"y_scale":{"type":"object","name":"LinearScale","id":"p1310"},"title":{"type":"object","name":"Title","id":"p1305","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1337","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1294","attributes":{"selected":{"type":"object","name":"Selection","id":"p1295","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1296"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"inbmPg=="},"shape":[1],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"CDT2Pw=="},"shape":[1],"dtype":"float32","order":"little"}],["topic",["Antiretroviral Therapy"]],["correctness",[true]],["questions",["What are the pharmacokinetics of Emtricitabine in HIV-infected pediatric subjects aged 13 to 17 years?"]],["agent_answer",["The pharmacokinetics of Emtricitabine (FTC) at steady state in HIV-1-infected pediatric subjects aged 13 to 17 years were determined in a study involving 27 subjects receiving a daily dose of 6 mg/kg up to a maximum dose of 240 mg oral solution or a 200 mg capsule. Of these, 26 out of 27 subjects received the 200 mg capsule.\\n\\nThe results showed mean \\u00b1 SD values for peak concentration (Cmax) and area under the curve (AUC) were 2.7 \\u00b1 0.9 \\u03bcg/mL and 12.6 \\u00b1 5.4 \\u03bcg\\u00b7hr/mL, respectively. These exposures achieved in pediatric subjects aged 12 to less than 18 years were similar to those achieved in adults receiving a once-daily dose of Emtricitabine."]],["reference_answer",["The pharmacokinetics of FTC at steady state were determined in 27 HIV-1-infected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg/kg up to a maximum dose of 240 mg oral solution or a 200 mg capsule. Mean \\u00b1 SD C and AUC were 2.7 \\u00b1 0.9 \\u03bcg/mL and 12.6 \\u00b1 5.4 \\u03bcg\\u2219hr/mL, respectively."]],["id",[99]],["content",["weighing &gt;40 kg, receiving the 600 mg dose of EFV, C\\n was 6.57 \\u03bcg/mL, C\\n was\\n2.82 \\u03bcg/mL, and AUC\\n was 254.78 \\u03bcM\\u2219hr.\\nEmtricitabine:\\n \\nThe pharmacokinetics of FTC at steady state were determined in 27 HIV-1-\\ninfected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg/kg up to\\na maximum dose of 240 mg oral solution or a 200 mg capsule; 26 of 27 subjects in this\\nage group received the 200 mg capsule. Mean \\u00b1 SD C\\n and AUC were 2.7 \\u00b1 0.9\\n\\u03bcg/mL and 12.6 \\u00b1 5.4 \\u03bcg\\u2219hr/mL, respectively..."]],["color",["#0a980a"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1338","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1339"}}},"glyph":{"type":"object","name":"Scatter","id":"p1334","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1335","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1336","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1351","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1342","attributes":{"selected":{"type":"object","name":"Selection","id":"p1343","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1344"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[181],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[181],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1352","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1353"}}},"glyph":{"type":"object","name":"Scatter","id":"p1348","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1349","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1350","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1306","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p1321"},{"type":"object","name":"WheelZoomTool","id":"p1322","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1323","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1324","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1329"},{"type":"object","name":"SaveTool","id":"p1330"},{"type":"object","name":"HoverTool","id":"p1297","attributes":{"renderers":[{"id":"p1337"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1316","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1317","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1318"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1319"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1311","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1312","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1313"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1314"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1315","attributes":{"axis":{"id":"p1311"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1320","attributes":{"dimension":1,"axis":{"id":"p1316"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1340","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1341","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p1337"}],"index":0}}]}},{"type":"object","name":"LabelSet","id":"p1357","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p1354","attributes":{"selected":{"type":"object","name":"Selection","id":"p1355","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1356"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"nsYOQIzvL0A="},"shape":[2],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"NeIpQKMV274="},"shape":[2],"dtype":"float32","order":"little"}],["topic",["Antiretroviral Therapy","Antiretroviral Therapy Interactions"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"f17ed850-2d57-4486-b267-b862bfc98f2d","roots":{"p1362":"c05476d2-835e-4833-be04-5f658c8c7a67"},"root_ids":["p1362"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="c05476d2-835e-4833-be04-5f658c8c7a67" data-root-id="p1362" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
